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ABSTRACT 
Disruption of the Wnt canonical signalling leads to the development of osteoarthritis both in 
human and in mice but the underlying molecular mechanisms are poorly understood. Both 
forced activation and blockade of Wnt/β catenin signalling lead to cartilage breakdown. This 
study attempts to unravel the mechanisms leading to such paradox and is based on the 
hypothesis that WNT-3A triggers multiple signalling pathways simultaneously, with distinct 
outcomes. 
WNT-3A-stimulation induced activation of Wnt/β-catenin pathway in articular chondrocytes 
and promoted proliferation and loss of chondrocytes phenotype markers, such as COL2A1, 
Aggrecan and SOX9 mRNA. However, whereas the inhibition of the Wnt/β-catenin pathway by 
DKK1 rescued the proliferative effect of WNT-3A, it did not rescue the loss of chondrocyte 
phenotype but, paradoxically, it further enhanced it. Therefore I tested the possibility that 
WNT-3A-induced chondrocyte de-differentiation could be mediated by other WNT pathways 
independent of β-catenin. Indeed, in AHAC WNT-3A induced intracellular calcium mobilization 
and phosphorylation and nuclear localization of CaMKII in a G-protein dependent manner, 
suggesting the activation of the Wnt/CaMKII pathway. 
Inhibition of the Wnt/CaMKII pathway rescued the loss of the phenotypic markers SOX9 and 
COL2A1 induced by WNT-3A, indicating that this pathway drives WNT-3A-induced chondrocyte 
de-differentiation. Finally, my data show that the Wnt/β-catenin and the Wnt/CaMKII 
pathways are mutually inhibitory, explaining why both exogenous WNT-3A and its inhibitor 
DKK1 lead to chondrocyte de-differentiation: the first through direct activation of CaMKII, and 
the second indirectly by removal of the inhibition of CaMKII exerted by the β-catenin pathway. 
My results show for the first time that a single WNT ligand can simultaneously activate at least 
two different pathways in the same cells with different outcomes. These findings highlight the 
possibility to therapeutically target individual outcomes of Wnt signalling, for instance to 
prevent chondrocyte de-differentiation without affecting crucial anabolic processes such as 
cell proliferation. 
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Once upon a time, there was a little girl named Goldilocks. *…+ 
At the table in the kitchen, there were three bowls of porridge. Goldilocks was hungry. She 
tasted the porridge from the first bowl.  
"This porridge is too hot!" she exclaimed. 
So, she tasted the porridge from the second bowl. 
"This porridge is too cold," she said. 
So, she tasted the last bowl of porridge. 
"Ahhh, this porridge is JUST RIGHT," she said happily and she ate it all up. 
From “The story of Goldilocks and the three bears” 
 
Any intelligent fool can make things bigger and more complex... It takes a lot of courage to 
move in the opposite direction 
Albert Einstein  
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BACKGROUND 
Activation of Wnt-mediated signalling cascades is associated with many biological processes, 
from embryo development to the maintenance of the homeostasis of adult tissues. 
In particular, modulation of the Wnt/β-catenin signalling has been demonstrated to be of 
paramount importance for joint formation (Guo et al., 2004;Hartmann and Tabin, 
2001;Koyama et al., 2008) and for chondrocyte differentiation (Church et al., 2002;Goldring, 
2006;Yamaguchi et al., 1999). 
The concept that WNT/β-catenin signalling plays an important role in osteoarthritis (OA) is 
now established not only for the abundant data demonstrating activation of this pathway in 
OA cartilage (Dell'Accio et al., 2008;Zhu et al., 2009) but also for the genetic association of 
mutations that result in disregulation of Wnt signalling with OA predisposition (Lories et al., 
2006;Loughlin et al., 2004;Lories et al., 2006;Loughlin et al., 2004) and several functional 
studies both in vitro and in vivo (Akiyama et al., 2004;Koyama et al., 2008;Ryu et al., 2002;Ryu 
and Chun, 2006). 
However, paradoxically, both activation and repression of this signalling cascade result in OA 
(Chen et al., 2008;Koyama et al., 2008;Lories et al., 2007;Zhu et al., 2008;Zhu et al., 2009). 
The aim of this study was to understand the molecular basis of this paradox and to test the 
hypothesis that individual Wnt ligands can modulate chondrocyte phenotype through multiple 
signalling pathways each with individual outcomes. 
Before describing my work, I will provide an overview of general cartilage biology, 
osteoarthritis and Wnt signalling. 
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LIMB DEVELOPMENT:  
The appendicular skeleton develops from the lateral plate mesoderm within the limb buds 
which are constituted by a core of mesenchymal cells covered by a layer of ectoderm 
(Karsenty, 2003). The limb buds are first visible in the human embryo after 4 weeks from the 
beginning of the gestation. According to a well-established model (Tickle, 1994;Fallon and 
Kelley, 1977) the morphogenesis of the limb bud is regulated by two signalling centres: the 
apical ectodermal ridge (AER), which, through the secretion of fibroblast growth factor 8 
(FGF8) regulates the proximo-distal axis acting within a specialized area of the limb bud 
mesenchyme called the progress zone (Fallon et al., 1994;Niswander and Martin, 1992;Sun et 
al., 2002;ten Berge et al., 2008) and the zone of polarizing activity (ZPA), which regulates the 
anterior-posterior axis through the formation of a gradient of the morphogen Sonic Hedgehog 
(Shh) (Niederreither et al., 1999;Drossopoulou et al., 2000). Finally, the secretion of WNT-7A 
by the dorsal ectoderm determines the dorso-ventral axis (Kengaku et al., 1997;Parr and 
McMahon, 1995)(Fig. 1). 
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Figure 1: Limb patterning 
A) Geometry of the limb bud. white: ectodermal layer, blue: dorsal mesenchyme, green: ventral 
mesenchyme. Red line indicates the dorso-ventral boundary (solid - posterior, dashed - anterior). The 
thick grey lines represent the flank, with the dots indicating the points of cross-section between the 
posterior and the dorsal view. B) Expression domains of patterning signals. The AER, expresses FGF 
encoding genes (such as Fgf8). The ZPA, is the source of Sonic Hedgehog (Shh). Figure modified from 
Kicheva and Briscoe (Kicheva and Briscoe, 2010). 
 
Positional information along all the axes needs to integrate with each other in order to ensure 
the proper limb pattern. How the different structures of a limb are determined during limb 
development, is still under debate. A theory proposes that the amount of time the 
undifferentiated cells spend within the progress zone specifies the position and the identity 
that these cells will acquire in the developed limb (Summerbell et al., 1973). According to a 
Introduction 
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more recent theory (Dudley et al., 2002), cells in the progress zone would acquire their 
positional identity immediately after limb bud formation and they would retain it during the 
growth of the limb (Dudley et al., 2002)(Fig. 2). 
 
 
Figure 2: Progress zone model vs early specification model  
a) The progress zone (PZ) model proposes that the final position of a cell in the developed limb is 
determined as the cell leave the progress zone (in green) at the edge of the limb bud. b) The early 
specification model proposes that the positional information is acquired already in the early limb bud. 
The cells then undergo considerable expansion before becoming determined to form the different 
skeletal elements, as indicated (Mariani and Martin, 2003). 
SKELETOGENESIS 
Different types of tissues originate from the limb bud mesenchyme, including cartilage, 
perichondrium, tendons, connective tissue and dermis (Pearse et al., 2007;SEARLS, 1965;Stark 
and SEARLS, 1973). Myogenic cells migrate from the somite into the limb bud, differentiating 
following a pattern determined by the interaction of these precursors with the connective 
tissue (Kieny et al., 1979;Kieny and Chevallier, 1979;Chevallier et al., 1978;Chevallier et al., 
1977). Soon after the formation of the limb bud, the mesenchymal cells condensate in the 
centre to form a chondrogenic core (Fig. 3a) (Kronenberg, 2003). Mesenchymal cell 
condensation is mediated by cell-cell and cell-matrix interactions. N-cadherin and Neural Cell 
Introduction 
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Adhesion Molecule (N-CAM) mediate cell-cell adhesion and are important for the initiation and 
maintenance of condensation (Widelitz et al., 1993;DeLise and Tuan, 2002a;DeLise and Tuan, 
2002b;Molenaar et al., 1996;Oberlender and Tuan, 1994b;Oberlender and Tuan, 1994a). Cell-
matrix interactions are instead mediated by fibronectin, cartilage oligomeric protein (COMP), 
tenascin, and syndecans (DeLise et al., 2000). 
The cells at the periphery of the condensation core become flattened and elongated and start 
forming the perichondrium (Goldring, 2006).  
Soon after condensation, the cells in the centre of the condensation (diaphysis) undergo 
chondrogenesis and deposit large amounts of cartilage-specific extracellular matrix. 
Chondrocyte differentiation is associated with the expression of the transcription factor SRY 
(sex determining region Y)-box 9 (Sox9) (Bi et al., 2001;Akiyama et al., 2004). Sox9 is strictly 
required for chondrogenesis and directly drives the expression of collagen type 2 (ColII), the 
hallmark of cartilage tissue (Akiyama et al., 2007).  
Afterwards, the cartilage anlagen become segmented, and, within the individual skeletal 
elements, chondrocytes undergo a coordinated process of proliferation and maturation which 
culminates in hypertrophy. Hypertrophic chondrocytes undergo terminal differentiation, 
driving the secretion of mineralized cartilage and the invasion of the cartilage anlagen with 
blood vessels, after which they undergo apoptosis. With vascular invasion, several cell types 
populate the cartilage anlagen including chondroclasts/osteoclasts, which degrade the matrix, 
and osteoblasts, which form bone at the expense of the cartilaginous template. This process is 
known as endochondral bone formation (Goldring, 2006;Shimizu et al., 1997)(Fig. 3). 
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Figure 3: Endochondral bone formation 
a) Mesenchymal cell condensation b) Differentiation of mesenchymal cells into chondrocytes (c) c), 
Hypertrophic maturation starts from the centre of condensation (h) d) Perichondrial cells adjacent to 
hypertrophic chondrocytes differentiate into osteoblasts, forming bone collar (bc). Hypertrophic 
chondrocytes direct the formation of mineralized matrix, attract blood vessels, and undergo apoptosis 
e) Osteoblasts accompany vascular invasion, forming the primary spongiosa (ps) f) Chondrocytes 
continue to proliferate, lengthening the bone. Osteoblasts of primary spongiosa are precursors of 
eventual trabecular bone; osteoblasts of bone collar become cortical bone (Kronenberg, 2003) 
SYNOVIAL JOINT FORMATION 
As mentioned previously, the appendicular skeletal elements originate from segmentation of 
continuous anlagen of condensed mesenchymal cells. Such process of segmentation is at the 
basis of synovial joint formation. The first step in joint formation is the condensation of 
mesenchymal cells in structures called joint interzones. Joint interzones are constituted by 
densely packed flattened cells, oriented with their major axis perpendicular to the major axis 
of the condensation, connected by gap junctions, clearly demarcating the future site in which 
the articular surfaces of two adjacent bones will face each other (Fig. 4). The cells of the joint 
interzone have been demonstrated to give origin to the permanent articular cartilage, 
Introduction 
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synovium, tendons, ligaments and joint capsule (Koyama et al., 2008;Pacifici et al., 2006). 
Interzone cells express several molecular markers including GDF5/CDMP1 (Chang et al., 
1994;Storm and Kingsley, 1999), Noggin, a BMP antagonist (Brunet et al., 1998), CD44, 
receptor for hyaluronic acid (Edwards et al., 1994), autotoxin, lubricin, the COL2A1-A splicing 
isoform (Gao et al., 2011;Koyama et al., 2008;Sandell et al., 1991;Sandell et al., 1994) and are 
known to differentiate into chondrocytes when cultured in vitro (Pacifici et al., 2006). In 
addition, some members of the Wnt family – WNT-4, WNT-14 and WNT-16 - are early and 
specific markers of the joint interzones (Guo et al., 2004;Hartmann and Tabin, 2001) and 
mediate the activation of the Wnt/β-catenin pathway at the site of joint formation (Guo et al., 
2004;Hartmann and Tabin, 2001;Koyama et al., 2008). 
The joint interzones are formed by three layers of cells. The middle one is composed of very 
packed cells believed to give rise to the articular cartilage, in which cells express increasing 
levels of hyaluronan (HA), promoted by mechanical stimulation of the developing limb 
(Dowthwaite et al., 1998;Dowthwaite et al., 1999;Osborne et al., 2002;Pitsillides et al., 1995). 
High concentrations of HA leads to the saturation of the hyaluronan receptor CD44, followed 
by cell apoptosis and consequent joint cavitation (Toole, 1990). The outer layers of the cells in 
the interzone participate in the growth of the anlagen (Ito and Kida, 2000) and further 
differentiate into the cells of the different tissues of the joint (Koyama et al., 2008). 
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Figure 4: Synovial joint formation 
A: Condensation of mesenchymal cells B: Partially understood mechanisms determine the site of 
synovial joint formation C: Formation of the joint interzone. In the meantime, the rest of the condensed 
mesenchymal cells differentiate into chondrocytes and establish the cartilage elements. D: Beginning of 
the cavitation process which will eventually lead to physical separation of the adjacent skeletal anlagen 
and formation of a synovial cavity. E: Morphogenetic processes begin to mold the opposing sides of the 
joint into reciprocally-shaped and interlocking structures. F: Differentiation of the mesenchymal cells in 
the distinct components of the mature synovial joint tissues (Pacifici et al., 2005). 
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THE ARTICULAR CARTILAGE 
Articular cartilage is the avascular connective tissue covering the surfaces of the diarthrodial 
joints. Its function is to allow a frictionless motion and to support and distribute loads on the 
underlying bone.  
Articular cartilage is mainly constituted by a highly hydrated extracellular matrix (ECM), 
composed by collagens and proteoglycans which surround the only cell type present in the 
tissue, the chondrocyte.  
The articular cartilage can be divided into four different zones, in which ECM and chondrocytes 
differ respectively in composition and in the expression of biochemical markers (Fig. 5). The 
most superficial zone is characterized by the presence of flattened chondrocytes expressing 
lubricin, an O-linked glycosylated protein first identified in the synovial fluid (Swann et al., 
1985), important for the lubrication of the articular surface and inhibiting the overgrowth of 
synovial cells at the same time (Flannery et al., 1999;Rhee et al., 2005). Chondrocytes in this 
zone are surrounded by collagen fibres running parallel to the surface of the tissue. 
Chondrocytes of the middle or transitional zone have a more rounded shape and collagen 
fibres are organized in arches in which tangential fibres from the superficial zone become 
perpendicularly orientated and are in continuity with those in the deep zone. In the deep zone, 
chondrocytes are organized in columns and here the concentration of proteoglycans is the 
highest. In the calcified zone chondrocytes express type X collagen (ColX) and alkaline 
phosphatase (AP) and have a hypertrophic phenotype (Linsenmayer et al., 1986). 
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Figure 5: Organization of the articular cartilage 
Articular cartilage can be divided in 4 different morphological and functional areas, as indicated by the 
figure (Poole et al., 2001). 
 
The composition of the ECM varies depending on their proximity to the chondrocytes and 
therefore three different regions can be distinguished in the healthy articular cartilage. The 
ECM immediately surrounding the chondrocyte is called pericellular matrix and it is enriched in 
collagen type VI (ColVI) (Poole et al., 1988) and perlecan (Costell et al., 1999), along with 
membrane-associated proteins such as fibronectin, allowing the anchorage of chondrocytes to 
the ECM. The areas surrounding clusters of chondrocytes or with the higher cellular density 
are instead defined as intraterritorial matrix. It is mainly constituted by collagen type II (ColII) 
and chondroitin sulphate proteoglycans forming a tight framework. Finally the remaining part 
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of the ECM is called interterritorial matrix, and it is manly acellular. Here collagens and 
proteoglycans are arranged as described for each layer in Fig. 5. 
THE CHONDROCYTE 
The only cell type present in the articular cartilage is the chondrocyte. Chondrocytes are round 
shape cells of approximately 13µm of diameter sitting in matrix cavities called lacunae. They 
represent between the 5 and the 10% of the total cartilage volume. Their role is to support and 
maintain the trophism of the cartilage matrix (Lin et al., 2006). Articular cartilage is an aneural, 
avascular and alymphatic tissue, therefore chondrocytes must rely on diffusion of metabolites 
and nutrients for their sustenance.  
As opposed to the epiphyseal chondrocytes which are responsible for the formation of the 
cartilage anlagen and are replaced by bone during endochondral bone formation, articular 
chondrocytes are phenotypically stable through their life, are resistant to vascular invasion and 
endochondral bone formation (Dell'Accio et al., 2001). From a topological point of view it 
might be tempting to speculate that articular chondrocytes originate from the growth plates 
and escape terminal differentiation. However, recent lineage tracking studies using the Cre-
LoxP technology have confirmed that articular chondrocytes differentiate from interzone cells 
and therefore have a distinct embryological origin acquired very early on during skeletogenesis 
(Koyama et al., 2008) 
Articular chondrocytes are able to grow in anchorage independent conditions (Benya and 
Shaffer, 1982;Benya et al., 1978) and a have remarkable phenotypic stability that allows them 
to retain their phenotype in vitro for some passages (Benya and Shaffer, 1982) and even to 
form ectopic stable cartilage following intramuscular implantation in immunodeficient mice 
(Dell'Accio et al., 2001). Late passage chondrocytes can be partially and transiently re-
differentiated in anchorage independent culture, but do not re acquire their phenotypic 
stability and when implanted into damaged muscle, tend to differentiate into cells of the 
muscular lineage (Dell'Accio et al., 2003a).  
Introduction 
 25 
THE EXTRACELLULAR MATRIX: 
COMPOSITION: 
COLLAGENS:  
Fibrillar collagens are polymers composed by three α-polypeptide chains arranged triple helix. 
The mechanism of synthesis of collagen is described in Fig. 6. Depending on the collagen type, 
the three α-chains may either be identical or differ. The characteristic amino acidic sequence 
of all the types of collagens is constituted by the repetition of Gly-X-Y triplets, where X is very 
often a Proline (Pro) and Y a 4-hydroxyproline (Hyp), a post-translationally modified form of 
Pro catalysed by prolyl hydroxylase. The presence of Hyp gives a high stability to collagen, due 
to the higher formation of intramolecular hydrogen bonds, involving the interaction with 
molecules of water. The organization in fibres and the high stability of collagen make it 
responsible for the high resistance to tensile strength of articular cartilage (Voet and Voet, 
1995). The type of collagen mainly expressed in the articular cartilage ColII. ColII consists of 3 
α1 chains and is cross-linked and stabilised by fibril-associated collagens, type IX and type XI. 
ColVI is found within the pericellular matrix of cartilage where it contributes to chondrocyte 
attachment and ECM interactions (Poole et al., 2001;Guilak et al., 2006). ColX is expressed by 
hypertrophic chondrocytes and is hence found within the calcified layer (Eyre, 1991). 
 
 
 
 
Introduction 
 26 
 
 
 
Figure 6: Synthesis of collagen  
Collagen synthesis: a) The polypeptide chains are synthesized in the ribosomes and secreted into the 
lumen of the endoplasmic reticulum, where they are subjected to different post-translational 
modification such as hydroxylation of Pro and Lys and glycosylation of other amino acidic residues. b) 
The C-pro-peptides are then assembled in the characteristic triple helix and secreted in the extracellular 
space. The subsequent steps are c) cleavage of the N and C pro-peptides, d) spontaneous self-assembly 
of the resulting collagen molecules into fibrils, and e) formation of covalent crosslinks. Figure from 
(Myllyharju and Kivirikko, 2004) 
PROTEOGLYCANS: 
Proteoglycans are heavily glycosylated proteins, constituted by a protein core to which one or 
more glycosaminoglycan (GAG) chains are covalently attached. GAGs are long polysaccharide 
chains made by repetitions of disaccharide groups, each carrying an amino sugar and either a 
carboxylate or a sulphate group, conferring to these molecules a high negative charge. This 
negative charge attracts cations including Na2+, which increase the osmolarity of the cartilage. 
Due to this property, water molecules attracted into the tissue are retained within the 
macromolecular network of GAG chains amongst the collagen network, providing articular 
cartilage with its high resistance to compressive loads. 
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Different GAGs define the pool of proteoglycans present in the articular cartilage, the most 
expressed being chondroitin sulphate (CS), heparan sulphate (HS), keratan sulphate (KS), 
dermatan sulphate (DS) proteoglycans and hyaluronic acid (HA). 
The proteoglycans mostly expressed in the articular cartilage is aggrecan (Fig. 7). 
 
 
 
Figure 7: Structure of Aggrecan  
Aggrecan is composed by three globular domains (G1, G2, G3), and interglobular domain (IGD) and 
multiple KS and CS units (Doege et al., 1991). 
 
The protein core of aggrecan is constituted of three globular domains (G1, G2 and G3), each 
having cysteines which can participate to the formation of disulphide bonds (Doege et al., 
1991). G2 and G3 regions are separated by a long GAG chain made of KS and CS units. G1 is 
situated at the N-terminus of the protein and can be divided in three subdomains, A, B1 and 
B2. B domains are responsible for the interaction with HA (Watanabe et al., 1998). A molecule 
of HA may interact with as many as 100 molecules of aggrecan, giving origin to massive 
aggregates. Each of this interaction is stabilized by link proteins (Morgelin et al., 1988). The G3 
domain is at the C-terminus end, it is responsible for the proper post-translational modification 
of the molecule and its secretion (Roughley, 2006). 
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In addition to aggrecan, other smaller leucine-rich proteoglycans are expressed in the hyaline 
cartilage including the dermatan sulphate proteoglycans biglycan and decorin, the keratan 
sulphate proteoglycans fibromodulin and lumican (Roughley, 2006) and the heparan sulphate 
proteoglycan perlecan, abundant in the pericellular matrix directly surrounding the 
chondrocytes (Melrose et al., 2006). These proteoglycans account only for a small percentage 
of the total volume of the ECM and they do not contribute in a substantial way to the 
mechanical properties of the tissue. Nevertheless, besides contributing to stabilize the ECM 
(Knudson and Knudson, 2001), they play important roles in regulating cartilage homeostasis by 
binding and modulating the activity of growth factors, by establishing functional 
morphogenetic gradients, and by directly acting as signalling molecules (Echtermeyer et al., 
2009). 
The absence of genes involved in the synthesis or post-translational modification of heparan 
sulphate proteoglycans (HSPG) have been shown to lead to aberrant joint phenotypes, such as 
joint fusions and bone growth delay both in mouse and in zebrafish (Mundy et al., 
2011;Wiweger et al., 2010). In addition Syndecan-3, another HPSG, can bind bone 
morphogenetic protein 2 (BMP2) and modulate its activity during cartilage differentiation 
(Fisher et al., 2006). 
In human cartilage, HSPG perlecan has been shown to bind and sequester FGF2 (Vincent et al., 
2007) and FGF18/FGFR3 (Chuang et al., 2010), suggesting that this proteoglycan might be 
involved in chondrocyte response to mechanotransduction and in the modulation of 
proliferative signalling. Decorin, biglycan and fibromodulin bind the chondrogenic factor 
transforming growth factor β (TGFβ) (Hildebrand et al., 1994) and the same small 
proteoglycans also bind and modulate the activity of matrix metalloproteinase 13 (MMP13) 
(Zhang et al., 2010) an enzyme involved in matrix remodelling and OA pathogenesis (Mitchell 
et al., 1996). Recent studies also demonstrate that syndecan 4 (Syn 4) is involved in the 
activation of A-disintegrin and metalloproteinases with thrombospondin motifs 5 
(ADAMTS5)(Echtermeyer et al., 2009), a proteinase largely involved in cartilage degradation in 
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OA (Glasson et al., 2005;Glasson et al., 2004), and mice deficient of Syn 4 are protected from 
the development of the disease (Echtermeyer et al., 2009). 
Finally, HPSGs are also required to maintain the solubility (Fuerer et al., 2010) and activity (Han 
et al., 2005) of WNT proteins, morphogens involved in joint formation (Guo et al., 
2004;Hartmann and Tabin, 2001) and in the maintenance of adult tissue homeostasis 
(Dell'Accio et al., 2008;Eltawil et al., 2009;Nalesso et al., 2011).  
NON-COLLAGENOUS STRUCTURAL PROTEINS 
A small group of non-collagenous proteins and glycoproteins concur to promote the trophism 
of the ECM and the interactions between chondrocytes and the ECM. Cartilage oligomeric 
protein (COMP) binds to collagen type I (ColI) and ColII through zinc-dependent interactions 
and promotes collagen crosslinking (Shen et al., 1995). Chondronectin is a glycoprotein 
mediating the adherence of articular chondrocytes to the ECM, binding to CS, HA and ColII 
(Hewitt et al., 1982). 
Fibronectin is a heterodimeric molecule particularly abundant in the superficial layer of the 
articular cartilage and in the pericellular matrix. It has been shown to provide attachment to 
cartilage progenitor cells within the superficial layer, and support their phenotype 
(Dowthwaite et al., 2004;Williams et al., 2010) and therefore may play a role in the guidance 
and regulation of these important cells in homeostatic processes and in cartilage healing. 
Fibronectin expression, limited to the superficial layer in normal cartilage, is increased in the 
deeper layer in OA (Homandberg, 1999). Fragments of this protein have been shown to 
activate catabolic pathways, including upregulation of MMPs and aggrecanases (Xie and 
Homandberg, 1993). 
ECM TURNOVER 
Chondrocytes are responsible both for the synthesis and the degradation of the extracellular 
matrix. A fine-tuned homeostatic equilibrium between catabolic and anabolic activities 
maintains the integrity of healthy articular cartilage.  
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CATABOLIC FACTORS 
METALLOPROTEINASES 
The main players in the ECM turnover are the different classes of metalloproteinases, the 
synthesis and the activity of which is modulated by chondrocytes. In the following paragraph I 
will limit the description of these enzymes to their biochemical structure and I will give an 
overview of their function and activity in the section concerning the pathogenesis 
osteoarthritis, since the major role that these enzymes play in this process. 
Metalloproteinases are divided in 5 families: the serralysins, the astacins, the ADAMTS, the 
MMPs and the pappalysins (Barrett, 1979). They are mainly responsible for the turnover of the 
ECM, but they are also responsible for the cleavage of other proteinases, proteinase inhibitors, 
growth factor binding proteins, chemotactic molecules, cell surface receptors and cell-cell 
adhesion molecules (Rengel et al., 2007). 
The most expressed metalloproteinases in the joint are the MMPs and the ADAMTS. The 
activity of both these classes of enzymes is modulated by their inhibitors, the tissue inhibitors 
of metalloproteinases (TIMPs). 
MMPS 
From a structural point of view (Rannou et al., 2006), MMPs are composed by three different 
domains: a pre-domain, responsible for enzyme maturation and its release from the cell, a pro-
domain, which maintain the enzyme in an inactive status (zymogen), and the catalytic domain, 
containing a zinc atom, which is required for the proteolytic activity of MMPs. MMPs are 
produced in an inactive form and require the cleavage of the pro-domain by other proteinases 
to become active. MMPs have been divided in 5 different classes: collagenases (MMP-1, MMP-
8 and MMP-13), capable to cleave collagens at neutral pH, gelatinases (MMP-2 and MMP-9), 
able to further degrade collagens fragments generated by collagenases, stromelysins (MMP-3, 
MMP-10 and MMP-11), which can cleave many substrates such as proteoglycans and 
fibronectin, matrilysins, and membrane type MMPs (MT-MMPs)(MMP-14; -15, -16, -17,-24 and 
-25). 
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Figure 8: MMPs 
Domain structure of secreted and membrane-anchored MMPs. Most MMPs contain a pro-peptide 
domain, a catalytic domain, a linker (hinge-region) and a C-terminal hemopexin (HPX)-like domain. 
Figure from (Hadler-Olsen et al., 2011) 
ADAMTS 
The ADAMTS are a family of 19 proteins sharing a number of structural features as outlined 
below and in Fig. 9 (Jones and Riley, 2005). Like MMPs, they contain a zinc ion within the active 
site, but differently from them, they exhibit narrower substrate specificity. From a structural 
point of view, ADAMTS possess a signal peptide, a pro-domain, which is cleaved within the cell 
to activate the enzyme, a metalloproteinase domain, a disintegrin domain, two or more 
thrombospondin motifs (TS) and several repeats at the C-terminus (Nagase and Kashiwagi, 
2003) (Fig. 9). 
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Figure 9: Molecular structure of ADAMTS 
Figure from (Jones and Riley, 2005). 
Two different subgroups of ADAMTS are expressed in articular cartilage: pro-collagen N-
propeptidases (ADAMTS-2, -3 and -14) are responsible for the removal of the telopeptides 
from ColI and ColII allowing fibrils formation (Fernandes et al., 2001). The other subgroup, 
composed by ADAMTS-1, -4, -5, -8, -9, -15 and -20, are also called aggrecanases: they in fact 
cleave aggrecan at a specific site between the G1 and G2 domains, at the Glu373-Ala374 bond in 
the IGD and at 4 additional sites located in the CS-enriched region (Tortorella et al., 2000). 
MMPs can cut aggrecan at the Asn341-Phe342 (Flannery et al., 1992;Sandy et al., 1992). 
TIMPS 
Metalloproteinases and aggrecanases activity is modulated at different levels: at a the 
transcriptional level, in response to inflammatory cytokines (such as, IL-1β, TNF-α) and growth 
factors (EGF, PDGF, FGFs and TGF-β) (Varghese, 2006); at the a post-translational level, 
through the activation of proteases which cleave MMP determining their activation, and 
finally, through their inhibition by specific inhibitors, the tissue inhibitors of metalloproteinases 
(TIMPs). 
Four TIMPs have been identified in humans, and they are more effective in blocking MMPs 
than ADAMTS activity (Baker et al., 2002). In homeostatic conditions, metalloproteinases and 
TIMP activity is tightly balanced. This equilibrium is disrupted in pathologic conditions such as 
OA, in favour of a higher catabolic activity (Dean et al., 1989). TIMP-3 in particular has been 
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shown to have a protective role in cartilage homeostasis, since TIMP-3 KO mice spontaneously 
develop OA (Sahebjam et al., 2007). 
ANABOLIC FACTORS 
Different growth factors and cytokines have been shown to have an anabolic effect in the 
articular cartilage. Insulin Growth Factor 1 (IGF1) and TGF-β have been shown to induce 
synthesis of highly sulphated GAGs in several in vitro systems (Morales, 1994;van Osch et al., 
1998;Luyten et al., 1988). In vivo, BMPs have the unique capacity to promote ectopic cartilage 
and bone formation (Urist, 1965;Wozney, 1995), can stimulate ECM synthesis and are thought 
to be involved in the regenerative process following cartilage damage (Blaney Davidson et al., 
2007;Dell'Accio et al., 2006;Volek-Smith and Urist, 1996). 
BMP and TGFβ signalling are important for the maintenance of cartilage homeostasis in 
physiologic conditions: mice deficient of BMP receptor 1 (BMPRI) spontaneously develop 
articular cartilage loss (Rountree et al., 2004) and absence of a TGFβ receptor II (TGFbRII) also 
results in cartilage damage through promotion of terminal differentiation and hypertrophy of 
articular chondrocytes (Serra et al., 1997). In humans, genetic polymorphisms in the members 
of the TGFβ superfamily-such as GDF5 and SMAD3- have been shown to be linked to a 
predisposition to develop OA, highlighting the importance of these molecules/signalling 
pathways to maintain cartilage integrity.  
Intra-articular injection of TGF-β in the mouse joint promotes proteoglycan synthesis (van 
Beuningen et al., 2000) and injection of TGF-β3 alone in rabbits efficiently induced the 
regeneration of severely injured articular cartilage (Warnke, 2010). Injection of mesenchymal 
stem cells isolated from perichondrium and infected with adenovirus encoding for BMP2 and 
IGF1 were also seen to have a reparative effect in the articular cartilage of rats in which partial 
thickness defect was performed (Gelse et al., 2003). In addition these two molecules together 
can block cytokine-induced ECM destruction and induce the expression of MMPs inhibitors 
(Hui et al., 2001). 
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Finally, mechanical loading, within physiological values, has been shown to promote the 
maintenance of cartilage health. Cyclical loading promote ECM synthesis (Larsson et al., 
1991;Valhmu et al., 1998) whereas immobilization of the joints is proved to be detrimental for 
the maintenance of the proteoglycans content in the ECM (Setton et al., 1995). 
Despite the knowledge of several signalling cascades and molecules involved in potential 
reparative processes after cartilage damage, few molecules are currently under clinical trial for 
treatment of cartilage diseases (TGF-β1 and BMP-7 are in phase 1 of clinical trials sponsored 
respectively by TissueGene and Stryker Biotech). This is due to the fact that some anabolic 
factors such as the members of the TGF-β superfamily, in addition to their potential 
regenerative properties, are also involved in endochondral bone remodelling after damage 
(Blaney Davidson et al., 2006;Scharstuhl et al., 2003;van Beuningen et al., 2000), and might 
bring to joint deformity if not opportunely modulated. Therefore, further studies are needed 
to have a better inside in the modulation of these pathways and how they cross-interact with 
each other, in order to plan an effective therapeutic strategy.  
CARTILAGE HOMEOSTASIS AND OSTEOARTHRITIS 
CARTILAGE HOMEOSTASIS 
Cartilage homeostasis is the maintenance of cartilage integrity and function through a fine-
tuned modulation of catabolism and anabolism. In physiologic conditions, the chondrocyte 
metabolism and matrix turnover are very slow. When injurious events, such as trauma, 
mechanical stress or inflammation challenge the articular tissue, a rapid anabolic response 
follows the initial catabolic events, in order to maintain homeostasis (Dell'Accio and Vincent, 
2010;Buckwalter and Mankin, 1998). 
When this equilibrium is broken and the anabolic activity cannot compensate anymore the 
injurious factors, cartilage is progressively lost, ultimately resulting in the development of OA 
(Bay-Jensen et al., 2010). 
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OSTEOARTHRITIS 
OA is a leading cause of disability worldwide, affecting up to 1/3 of the population over the age 
of 50 (Lawrence et al., 1998;Lawrence et al., 2008) and costing £5.7 billion annually only in the 
UK (Arthritis care report, 2007).  
The aetiology of primary OA is unknown: the incidence of the disease increases with age 
(primary osteoarthritis) but it can also develop following a joint injury or as a consequence of 
developmental, metabolic or neurological disorders (secondary osteoarthritis) (Buckwalter and 
Mankin, 1998).  
Cartilage breakdown is the hallmark of OA but cartilage is not the only tissue involved. In OA, 
virtually every tissue is involved in the pathological process. The changes in the subchondral 
bone include an initial phase of bone resorption, and a subsequent phase culminating in a 
characteristic bone sclerosis (Buckwalter and Mankin, 1998) meniscal and ligament lesions can 
be either primary and themselves driving OA progression (Englund et al., 2009) or secondary 
(Buckwalter and Mankin, 1998). The synovial membrane may also play an important role 
either supporting the inflammatory process (Sellam and Berenbaum, 2010) and then 
contributing to a pathogenic mechanism, or possibly can produce progenitor cells important 
for reparative mechanisms (De Bari et al., 2001;Karystinou et al., 2009). Finally, the geometry 
of the joint is also altered by the presence of osteophytes and by bone remodelling events and 
this is known to further contribute to cartilage loss (Wluka et al., 2005). 
In the interest of brevity and focus, in this thesis, I will limit this introduction to describe the 
pathogenic processes within the cartilage. 
From a histological point of view, the first signs of OA are the fibrillation of the superficial 
layers of the articular cartilage, followed by a progressive loss of proteoglycan content 
(Buckwalter and Mankin, 1998). In the majority of the cases, as the disease progresses, 
fibrillations become clefts and fissures that can reach the calcified areas and the subchondral 
bone.  
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During the early phases of OA the articular cartilage can show hypercellularity, resulting from 
the increased proliferation of chondrocytes (Mankin, 1974a;Mankin, 1974b), especially near 
the damaged areas (clustering). In the later stage of the disease, when the ability of 
chondrocytes to counterbalance the catabolic processes is compromised, there is a decline in 
their anabolic response, followed by cell death and areas of hypocellularity (Mankin, 
1974a;Mankin, 1974b).  
Unfortunately, no treatment for OA is currently available, except for pain control and 
physiotherapy, until prosthetic joint replacement is required.  
Understanding the pathogenetic mechanisms leading to the disruption of homeostasis and 
cartilage breakdown is of paramount importance to develop effective pharmacological 
treatments.  
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Figure 10: Graphic representation of an osteoarthritic knee 
Main features of advanced osteoarthritis are the degradation of the articular cartilage, with consequent 
exposure and damage of the subchondral bone, bone remodelling, with formation of bone spurs and 
osteophytes and degeneration of other articular tissues, such as the synovium and the menisci (Figure 
from the NHS website).  
PHENOTYPIC MODULATION OF CHONDROCYTES IN OA 
In healthy cartilage, chondrocytes support and stabilize the ECM, favouring a low rate turnover 
of the matrix components. After injury and in the early phases of OA, chondrocytes increase 
their anabolic activity, in a regenerative attempt to restore the lost homeostasis. 
In this phase chondrocytes produce and secrete an increased amount of matrix components, 
such as ColII, ColVI Col IX and ColXI as well as Aggrecan (Lorenz et al., 2005). 
In OA, articular cartilage chondrocytes change their phenotype in a hypoxia induced factor 
(HIF)2α-dependent manner and acquire features of hypertrophy, expressing COLX, VEGF, and 
MMP 13 (Saito et al., 2010), and such phenotypic change has pathogenetic importance, since 
the deletion of HIF2α gene resulted in halting the hypertrophic differentiation of articular 
chondrocytes following DMM and in resistance to OA cartilage damage (Saito et al., 2010;Yang 
et al., 2010). 
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During OA progression, the equilibrium between anabolic and catabolic activity is disrupted in 
favour of the latter with increased expression and activity of MMPs and ADAMTS, with a 
consequent degradation of the ECM.  
MATRIX TURNOVER IN OA 
ROLE OF MMPS IN OA PATHOGENESIS 
The degradation of the ECM by MMP activity is required for many homeostatic mechanisms, 
such as cell migration (Goetzl et al., 1996), tissue remodelling during development and after 
damage (Page-McCaw et al., 2007), release of proteoglycan-bound cytokines and morphogens 
(Dierker et al., 2009). Consequently, disruption of the modulation of MMP activity has been 
shown to be involved in different pathologies, from cancer, where tissue degradation 
promoted by MMPs leads to tumour invasiveness (Gialeli et al., 2011) to osteoarthritis, where 
they contribute to cartilage destruction. The expression of several MMPs is increased in 
cartilage from OA patients (Kevorkian et al., 2004). Constitutive expression of MMP-13 under 
control of ColII-promoter, resulted in increased cartilage degradation in a murine model of 
osteoarthritis (Neuhold et al., 2001) in comparison to wild type littermates. Conversely, 
MMP13 deficient mice were protected from instability induced OA (Little et al., 2009). In the 
SRT/Ort mice, a strain of mice which spontaneously develop OA (Walton, 1977;Walton, 
1978;Mason et al., 2001), expression of MMPs is higher in comparison to CBA mice which do 
not develop the disease. Indeed, oral administration of a selective inhibitor of MMP1, MMP8 
and MMP13 protected cartilage from damage in these mice (Brewster et al., 1998). On the 
contrary, MMP-3 knock-out mice develop more severe articular damage OA in comparison to 
wild type controls (Chambers et al., 2001). Furthermore, a mutation in the gene encoding for 
Aggrecan that makes the protein resistant to MMP cleavage, not only does not protect these 
mice from the development of OA but actually make them more susceptible to the 
development of the disease (Little et al., 2007). These data suggest that a tightly regulated 
MMP activity is required for cartilage homeostasis, but, in pathology, uncontrolled MMPs 
activity may become a pathological mechanism. The requirement of MMP activity for the 
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maintenance of cartilage homeostasis might explain why inhibition of MMPs activity failed to 
provide an efficacious treatment for OA (Tu et al., 2008) and warrants further research to seek 
a greater level of specificity and control for MMP inhibition in OA.  
ROLE OF ADAMTS IN OA PATHOGENESIS 
Aggrecan fragments generated by ADAMTS can be detected using antibodies specific for the 
proximal and distal stubs (Calabro et al., 1992) and are increased in the cartilage and in the 
synovial fluid of osteoarthritic and rheumatoid arthritis patients (Struglics et al., 2006;Sandy et 
al., 1992). Mice harbouring a mutation in the intraglobular domain of aggrecan, which makes 
the molecule resistant to ADAMTS cleavage, are protected from cartilage damage in the early 
onset of osteoarthritis in the destabilization of the medial meniscus (DMM) model (Little et al., 
2007). In arthritis, at least in mouse, ADAMTS5 is the main aggrecanase, since mice deficient in 
the ADAMTS5 gene are protected from cartilage destruction in an experimental model of OA 
(Glasson et al., 2005) and inflammatory arthritis (Stanton et al., 2005). In the human cartilage 
however, ADAMTS4 may have a more important role (Yang et al., 2010;Bondeson et al., 
2008;Davidson et al., 2006). In addition, although ADAMTS5 function is well established in OA, 
it is not clear whether it has any function in the normal remodelling of the ECM in healthy 
cartilage, since ADAMTS5 deficient mice are phenotypically normal, and, in physiological 
conditions, ADAMTS5 is not even expressed in cartilage (McCulloch et al., 2009). 
ROLE OF INFLAMMATION IN OA 
The role of inflammation in osteoarthritis is not as prominent as in inflammatory arthritides 
such as rheumatoid arthritis (RA) (Buckwalter et al., 2005). However, several pro-inflammatory 
molecules such as interleukin-1 (IL-1) and tumour necrosis factor α (TNF-α) are abundantly 
expressed in the synovial fluid of OA patients (Saklatvala, 1986;Rowan et al., 2001;Bondeson et 
al., 2006) suggesting that at least in the initial phases, inflammation might play an important 
role in OA pathogenesis. 
OA chondrocytes have an increased expression of IL-1β, IL-1β converting enzyme, IL-1β 
receptor type I, TNFα and IL-6 (Guerne et al., 1990;Kobayashi et al., 2005;Moos et al., 
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1999;Umlauf et al., 2010). IL-1 has been shown to promote MMPs and ADAMTS5 activity 
(Tetlow et al., 2001) and to induce rapid degradation of the ECM (Saklatvala, 1987). Recently, 
in a murine model of osteoarthritis, Syndecan-4 deficient mice have been shown to be 
protected by OA development, through a mechanism in which IL-1 seems to have a 
protagonist role (Eichtermeyer et al., 2009). IL-1β can suppress the expression of ColII, to 
increase that one of hypertrophic markers such as MMP13 (unpublished material) and finally 
to promote the expression of other pro-inflammatory cytokines such as IL-6 and IL-8 (Goldring 
and Berenbaum, 2004). 
Finally, both IL-1 and TNF-α can stimulate nitric oxide (NO) and prostaglandin production in 
articular cartilage (Palmer et al., 1993). Nitric oxide synthase (iNOS) is up-regulated in the 
cartilage of OA patients (Amin et al., 1995;Melchiorri et al., 1998) and its activation results in 
persistent biological effects including post-translational modification of the collagen network 
(Hughes et al., 2010). 
Despite there is evidence showing the negative role of inflammatory cytokines in OA 
development, some contrasting data show that basal levels of some of these molecules might 
also have a homeostatic role in the maintenance of articular cartilage homeostasis. The use of 
mouse genetics, in this field has in fact led to contrasting results. Clements et al. (Clements et 
al., 2003) reported that IL-1 deficient mice develop more severe OA than wild type controls in 
a surgical model of instability-induced OA. In contrast, IL-1β KO mice have been shown to be 
protected by articular cartilage damage in a different model of arthritis (collagenase induced 
OA) (Glasson, 2007). Blockade of NO production, as well as its IL-1-stimulated synthesis both 
result in an increased ECM degradation (Abramson, 2008;Stefanovic-Racic et al., 1996). 
The pharmacological blockade of IL-1 activity with the competitive antagonist of the IL-1 
receptor Anakinra, has been demonstrated to be effective in the reduction of proteolytic 
activity and osteophyte formation in a canine model of OA in comparison to control (Caron et 
al., 1996). On the contrary, a multi-centre clinical trial testing the beneficial of the use of 
Anakinra in humans, failed in decreasing pain and matrix degradation in OA patients (Chevalier 
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et al., 2009). Of course, this might be due to differences in the responsivity to the drug across 
species, but the fact that also the complete absence of IL-1, IL-1 converting enzyme, iNOS or 
MMP1 genes has been shown to be detrimental in the development of OA (Clements et al., 
2003) suggests that actually a basal activity of these molecules and enzymes is required for the 
maintenance of cartilage health.  
WNT SIGNALLING 
WNTs are a family of 19 morphogens known to regulate many developmental processes, such 
as tissue patterning, cell proliferation and migration (Logan and Nusse, 2004) and to maintain 
tissue homeostasis in the adult (Nusse, 2008). Given the multitude of processes in which they 
are involved, disregulation of Wnt pathways is associated with a variety of different diseases, 
from cancer (Clevers, 2006) to osteoarthritis (Lawrence et al., 1998;Lawrence et al., 
2008;Loughlin et al., 2004;Luyten et al., 2009;Zhu et al., 2008;Zhu et al., 2009). Being 
morphogens, Wnts are produced and secreted by cells, and form a concentration gradient 
which spread in the tissues (Neumann and Cohen, 1997;Zecca et al., 1996) and let the cells in 
the proximity to respond to it in a concentration-dependent manner, by promoting the 
transcription of cell specific target genes. Traditionally, Wnt ligands have been divided into two 
different groups depending on their ability to promote or not axis duplication in Xenopus 
embryos (McMahon and Moon, 1989). Wnts promoting axis duplication are known as 
“canonical Wnts” and activate the Wnt/β-catenin signalling pathway, also called for this reason 
“canonical” pathway. Among the members of this group there are WNT-1, WNT-3A and WNT-
8A. Non canonical Wnts-such as WNT-4, WNT-5A, WNT-5B, WNT-7A and WNT-11- do not 
promote axis duplication nor activate the Wnt/β-catenin pathway but other, less 
characterized, signalling cascades, grouped under the name of “non-canonical” signalling 
pathways. Recent overexpression experiments have questioned this rigid distinction proposing 
that, in some cases, the receptor repertoire may influence the downstream signalling pathway 
to the same ligand (Medina et al., 2000;Mikels and Nusse, 2006a;Tao et al., 2005;Heisenberg 
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et al., 2000), however the supra-physiological expression levels of the overexpressed gene in 
this type of experiments is such that "off target" or non-specific effects, which are not relevant 
at physiological expression levels cannot be excluded. Therefore the physiological significance 
of these findings remains uncertain. 
WNT LIGANDS 
On a structural point of view, all Wnts share common features including a signal sequence for 
secretion, several highly charged amino acidic residues and many glycosylation and lipid 
modification sites (Nusse and Varmus, 1992). They all share a sequence of 22 cysteine residues 
which are believed to be important for the protein folding (Mikels and Nusse, 2006b). 
 
 
Introduction 
 43 
 
Figure 11: Gene and protein structure of Wnts  
a) Gene structure of some members of the Wnt family. Exons are represented as boxes, and introns as 
lines. WNT-8 is an example of a gene which can be subjected to alternative splicing at the 3’terminus 
and WNT-16 can be subjected to different splicing at the 5’. CDS=Coding sequence b) at protein level all 
WNTs possess a signal sequence (S) for extracellular secretion, and 23/24 Cys residues (Miller, 2002). 
 
The sequence of Wnts is preserved across species: when compared, any two different WNTs 
normally share between the 30 and the 60% of similarity at aminoacid level, regardless of the 
species (Nusse and Varmus, 1992). The evolutionary preservation of these molecules 
underlines their important role. 
Glycosylation and lipid modification have been shown to be essential for their signalling 
properties and the stability of these proteins. Mutation of the glycosylation sites has been 
reported to compromise secretion (Kurayoshi et al., 2007;Komekado et al., 2007) whereas lipid 
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modification are thought to anchor them to the cell membrane and to be important both for 
secretion and signalling (Willert et al., 2003;Franch-Marro et al., 2008;Takada et al., 2006). 
Wnts can travel up to 20 cell diameters away from the cell in which they are produced (Zecca 
et al., 1996;Neumann and Cohen, 1997). The mechanism of diffusion and gradient formation 
of such hydrophobic molecules has not been clarified yet. Current hypotheses include that, 
upon translocation to the membrane, lipase or metalloproteinases may cleave the 
hydrophobic lipid modification of the proteins allowing the release outside of the cells, or that 
WNTs may be secreted inside micelle-like aggregates or on membranous particles (Port and 
Basler, 2010). Intriguingly, HSPGs have been shown to bind Wnts and to be involved in Wnt 
gradient formation in Drosophila (Han et al., 2005) and be important for their stability in 
human (Fuerer et al., 2010). Considering the high content of HSPGs in the articular cartilage, 
these molecules are very likely to play an important role in the formation of Wnt gradients in 
this tissue. 
FRIZZLED (FZD) RECEPTORS 
Wnts are known to interact with FZD receptors to mediate their signalling cascades. The basic 
structure of all FZD is that of seven transmembrane domain receptor, with an extracellular N-
terminus and an intracellular C-terminus. At the N-terminus all frizzled possess a Cys-rich 
domain (CRD) which probably represents the binding site for Wnt ligands (Xu and Nusse, 
1998). The transmembrane domain of FZD contains some similarities with G-protein-coupled 
receptors (GPCR) (Malbon, 2004) and indeed much evidence suggest that FZDs are GPCRs 
(Koval and Katanaev, 2011;Slusarski et al., 1997a). At the C-terminus, FZD share a KTxxxW 
domain (PDZ domain) which allows the interaction with Dishevelled (DVL), an adaptor protein 
important for the mediation of both canonical and non canonical pathways (Grumolato et al., 
2010). 
Several single transmembrane domain receptors have been shown to act as co-receptors for 
FZDs and to mediate different signalling cascades. Low density lipoprotein receptor-related 
Introduction 
 45 
receptors 5 and 6 (LRP5/6) interact with FZD receptors after binding of Wnts to FZDS and this 
interaction promotes their phosphorylation in the intracellular domain (Zeng et al., 2008). The 
formation of this ternary complex-Wnt/FZD/LRP-is essential for the activation of the Wnt-β-
catenin pathway (Nusse, 2005). Ten LRPs have been identified in human and have been shown 
to have important functions in endocytosis, cell-cell communication, embryonic development, 
and diseases (Li et al., 2001;May et al., 2007). 
ROR1/2 and RYK tyrosine kinases receptors heterodimerize with FZD receptor and can mediate 
Wnt non-canonical signalling autonomously, as FZD co-receptors, or both (Schulte, 2010). 
Abnormalities in ROR1/2 receptors have been associate with skeletal disorders (Minami et al., 
2010). Binding of Wnts to RYK trasduces important signalling involved in axon guidance and 
neurite autgrowth (Yoshikawa et al., 2001;Lu et al., 2004). However, the mechanism of 
activation and the signalling cascades mediated by these receptors are still not-well 
characterized and will require further investigation. 
WNT SIGNALLING PATHWAYS 
WNTs signal through multiple pathways (Semenov et al., 2007;Macdonald et al., 2007) the 
best characterized of which is the Wnt/β-catenin-dependent pathway. In this signalling 
cascade, in the absence of ligands, the constitutively active kinase glycogen synthase kinase 
(GSK)-3β phosphorylates β-catenin within a destruction complex, addressing it for degradation 
through the proteasome pathway (Logan and Nusse, 2004). The engagement of some 
members of the Wnt family, such as WNT-1 and WNT-3A (Logan and Nusse, 2004;Shimizu et 
al., 1997) with Frizzled (FZD) receptors and the co-receptors LRP5/6 results in the disruption of 
the destruction complex, accumulation of β-catenin in the cytosol, and its migration in the 
nucleus, where β-catenin interacts with T-cell factor (TCF)/ Limphoid enhancer binding-factor 
(LEF) transcription factors and supports the transcription of cell-specific target genes 
(Molenaar et al., 1996) involved in different biological processes, such as cell proliferation, 
apoptosis and cell determination (Moon et al., 2002). 
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Figure 12: Wnt/β-catenin dependent pathway 
Upon engagement with Wnt ligands, FZD receptors heterodimerize with LRP5/6 co-receptor and recruit 
axin to the cell membrane. This in turn promotes the destabilization of the destruction complex in which 
β-catenin is retained, allowing its accumulation in the cytoplasm. β-catenin then transmigrates in the 
nucleus and it interacts with TCF/LEF transcription factors, promoting the transcription of cell-specific 
genes (Moon et al., 2002). 
Other WNTs, such as WNT-5A and WNT-11 (Kuhl et al., 2000) can instead activate other β-
catenin independent signalling cascades, generally referred as “non-canonical” pathways. The 
best characterized of them is the planar cell polarity (PCP) pathway, which has been 
extensively studied in Drosophila, and which has been proved to modulate different biological 
processes such as the orthogonal polarity of the cells (Fanto and McNeill, 2004) and 
convergent extension movements, hair follicle orientation, and neural tube formation 
(Wallingford and Harland, 2001;Wang et al., 2006b;Wang and Nathans, 2007). 
Some FZD receptors have been shown to mediate intracellular calcium accumulation in 
response to WNT stimulation (Kuhl et al., 2000;Slusarski et al., 1997a;Slusarski et al., 1997b) a 
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mechanism which is G-protein mediated because it can be blocked by pertussis toxin (Kuhl et 
al., 2000;Sheldahl et al., 1999;Slusarski et al., 1997a). The increase in intracellular calcium has 
then been associated with the activation of different Ca2+-dependent pathways, such as the 
protein kinase C (PKC), calmodulin kinase II (CaMKII) and calcineurin (CNA) pathways. In 
particular the Ca2+/CamKII pathway has been shown to be important during development, 
driving ventral cell fate in Xenopus (Kuhl et al., 2000) and modulating differentiation and 
proliferation in the epiphyseal cartilage both in chicken (Taschner et al., 2008) and in mouse (Li 
et al., 2011). Finally, activation of CaMKII pathway has been shown to antagonize the β-
catenin- dependent pathway in different systems (Topol et al., 2003;Ishitani et al., 2003). 
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Figure 13: Non canonical Wnt signalling pathways 
In addition to the Wnt/β-catenin signalling, some Wnt ligands have been shown to activate several other 
signalling cascades which probably require the interaction of FZDs with co-receptor other than LRPs or 
are mediated by FZDs alone. The figure gives an overview of some of the pathways that have been 
described so far (Semenov et al., 2007). 
WNT INHIBITORS 
Wnt signalling can be antagonized at different levels. Of particular interest, in this thesis, are 
the secreted inhibitors of Wnt signalling. Different classes of soluble antagonists have been 
identified: among these Dikkopfs (DKK) and secreted frizzled related proteins (sFRPs) are the 
best characterized. Dkks - especially Dkk1 and 4 - bind to LRP5/6 and promote their 
heterodimerization with Kremen receptors (Mao et al., 2001). This coupling, in turn, promotes 
LRP internalization via a clathrin-mediated mechanism (Yamamoto et al., 2008). The removal 
of LRPs from the cell surface prevents the formation of the ternary complex Wnt/LRP/FZD and 
the activation of the canonical pathway (Bafico et al., 2001). Secreted frizzled related proteins 
(sFRPs) are a class of soluble inhibitors composed by 5 members with distinct expression 
patterns (Jones and Jomary, 2002). They bind to Wnts through their frizzled-related N-terminal 
domain and act as scavenger molecules, preventing the interaction with FZD receptors. 
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However, the role of these molecules is still not completely understood because they are also 
been proposed to be WNT agonists, acting as carriers for Wnts or modulating the 
concentration of Wnts in the cellular environment (Kawano and Kypta, 2003). 
WNT IN LIMB FORMATION AND SKELETAL PATTERNING 
A temporal and spatial finely tuned expression of WNTs has been shown to be crucial for limb 
development. In chicken, WNT-3A is expressed in the AER and promotes the expression of 
FGF8, through the activation of the β-catenin dependent pathway, sustaining the maintenance 
of the AER and the limb outgrowth (Kengaku et al., 1997;Kawakami et al., 2001). Similarly, in 
the mouse, inactivation of both TCF1 and LEF1, ultimate mediators of β-catenin signalling, 
prevents limb outgrowth (Galceran et al., 1999). 
Later in development, activation of the WNT/canonical pathway has been demonstrated to be 
required and sufficient for synovial joint formation (Guo et al., 2004;Hartmann and Tabin, 
2000) and abrogation of this signalling cascade results in joint fusions (Koyama et al., 2008). 
Conversely, inactivation of the canonical pathway is required for chondrocyte differentiation, 
since the overexpression of β-catenin in the limb mesenchyme represses the expression of 
Sox9 (Akiyama et al., 2004). 
Also the activation of the non-canonical pathways, plays a role in limb development: mice 
lacking of WNT-5A, which activates the Ca2+/CaMKII pathway both in Zebrafish and Xenopus 
(Slusarski et al., 1997b), have shorter limbs and a global retardation in development due to a 
delay in chondrocyte maturation (Yamaguchi et al., 1999). However, also overexpression of 
WNT-5A results in a similar phenotype of chondrodysplasia making of difficult interpretation 
its mechanism of action (Yang et al., 2003). 
Finally WNT-7A controls dorso-ventral patterning: the absence of WNT-7A promotes 
ventralization of several skeletal structures (Parr et al., 2001) a phenotype which is similar to 
that of LRP6-/- mice, leading to the hypothesis that WNT-7A requires LRP6 to mediate its 
signalling. 
Introduction 
 50 
WNT SIGNALLING IN TISSUE HOMEOSTASIS AND DISEASE 
In adult life, modulation of Wnt signaling has an important role in cartilage and bone 
homeostasis. Our group demonstrated activation of the canonical Wnt pathway in 
osteoarthritic cartilage in humans (Dell'Accio et al., 2006) and following cartilage injury in mice 
(Dell'Accio et al., 2008;Eltawil et al., 2009). Genetic studies revealed that loss of function 
polymorphisms in the SFRP3 and LRP5 gene (Gong et al., 2001;Mizuguchi et al., 2004;Riancho 
et al., 2011) are linked respectively to an increased susceptibility to OA (Loughlin et al., 
2004;Lories et al., 2007) and osteoporosis (Gong et al., 2001). Overexpression of Dkk1 has 
been shown to enhance bone erosion in a model of inflammatory arthritis (Diarra et al., 2007) 
and to mediate chondrocyte apoptosis in osteoarthritic cartilage (Weng et al., 2010). These 
data, together with other in vivo and in vitro experimental evidence suggest that the β-catenin-
dependent/Wnt pathway is a master regulation of joint remodelling (Luyten et al., 2009;Schett 
et al., 2008). 
However, results of functional studies using mouse genetics are contrasting and of difficult 
interpretation. For instance, both repression and forced activation of the canonical Wnt 
signalling resulted in chondrodysplasia in embryonic life (Akiyama et al., 2004) and in OA 
postnatally (Koyama et al., 2008;Lories et al., 2007;Zhu et al., 2009;Chen et al., 2008;Zhu et al., 
2008). Therefore further analysis is required to better clarify the role of this pathway in 
cartilage disease. 
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HYPOTHESIS 
This work tests the hypothesis that the maintenance of a fine-tuned equilibrium of Wnt-
mediated signalling cascades is required for the maintenance of chondrocyte phenotype. 
 
AIMS 
1) To evaluate the effect of the activation and repression of the Wnt/β-catenin signalling 
pathway on articular chondrocyte in vitro 
 Evaluation of the effect of the stimulation of human articular 
chondrocytes (AHAC) with a well characterized activator the Wnt/β-
catenin signalling pathway -WNT-3A- in presence or absence of a 
WNT/β-catenin inhibitor-DKK1 
2) To confirm these data in an in model of cartilage formation in vivo (Dell'Accio et al., 
2001). 
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For all the recipes of media and buffers please refer to the end of the “Materials and Methods” 
session. 
CARTILAGE HARVEST AND CHONDROCYTE ISOLATION  
Human adult articular cartilage was obtained from 10 female and 4 male patients who 
underwent joint replacement for knee osteoarthritis after obtaining consent. All procedures 
have been approved by the East London and The City Research Ethics Committee 3 (REC 
07/Q0605/29).  
Surgical samples containing bone and cartilage were immediately placed in a closed sterile jar 
to maintain moisture and sterility, and processed within 4 hours from the operation. Full 
thickness cartilage explants were dissected from the femoral condyles and the patellar groove 
in sterile conditions, excluding the mineralized cartilage and the subchondral bone. From each 
sample, one full thickness portion was processed for histological scoring. The sample was then 
cut and stained with toluidine blue and scored for features of OA as described below. The rest 
of the cartilage was washed twice in high-glucose Dulbecco's modified Eagle medium (D-
MEM/F-12 1:1 plus GlutaMax, Invitrogen) containing 10% v/v foetal bovine serum (FBS), 1mM 
sodium pyruvate (NaPyr), and 2% v/v antibiotic-antimycotic solution (Gibco, Invitrogen) for 10 
minutes at RT under rotation. Cartilage was then digested under slow agitation for 30 minutes 
at 37°C in 1mg/ml pronase (Roche) diluted in complete medium (same composition, with 1X 
antibiotic/antimycotic solution) and then overnight at 37°C in 1mg/ml collagenase P (Roche).  
CELL COUNTING AND TRYPAN BLUE EXCLUSION ASSAY.  
Ten μl of cell suspension was mixed 1:1 with a 0.5% of Trypan blue and immediately counted 
using a Neubauer haemocytometer. Cell viability as evaluated by trypan blue exclusion was 
routinely ≥ 95%. The cell suspension recovered from the isolation procedure was then 
resuspended in complete medium at 37oC in a humidified atmosphere with 5% CO2, seeded at 
a density of 104 cells/cm2, and allowed to attach for 7 days. At this point, non-attaching cells 
were removed by changing the medium.  
Materials and Methods 
 55 
Porcine chondrocytes were isolated from the metatarsal joints of pigs obtained from a local 
abattoir within 24 hours from the death of the animal, isolated and cultured with the same 
procedure. 
CELL EXPANSION 
Chondrocytes were cultured at 37°C in humidified atmosphere containing 5% CO2. The 
medium was replaced two times per week. 
For cell expansion, 80% confluent chondrocytes were split 1:4 upon attainment of confluency.  
To this end, cultures were washed once in Ca2+-, Mg2+- free PBS, incubated for 5 minutes with 
pre-warmed 0.025% Trypsin EDTA (Gibco) at 37oC, and detached by gentle tapping. Cells were 
immediately pelletted by centrifugation at 2000 rpm and re-plated.  
All the experiments were performed on freshly isolated or P0 cells as indicated within 7 days 
from the attainment of confluence.  
Only chondrocytes deriving from preserved cartilage areas (Mankin score ≤ 4) were used. 
Previous studies in our laboratory showed that such score is associated with a gene expression 
profile and responsivity to injury and Wnts very comparable to normal cartilage (Dell'Accio et 
al., 2008). 
HISTOLOGICAL SCORING  
The severity of OA in human cartilage explants was evaluated using Modified Mankin score 
(Mankin et al., 1971;van der Sluijs et al., 1992). The score goes from 0-normal cartilage- to 13-
severe cartilage lesions. This system assesses different aspects of the articular cartilage 
morphology and structure (Table 1). Staining for scoring was performed with Toluidine blue 
(see below). 
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TABLE 1: MANKIN SCORE 
Category score 
Structure  
Normal 0 
Slight disorganization (cellular row absent, some superficial clusters) 1 
Irregular surface, including fissures into the radial layer 2 
Pannus 3 
Superficial cartilage layers absent 4 
Fissures into the calcified cartilage layer 5 
Sever disorganization (chaotic structure) 6 
Cellular abnormalities  
Normal 0 
Hypercellularity 1 
Clusters 2 
Hypocellularity 3 
Matrix staining (Metachromasia)  
Normal 0 
Staining reduced I radial layer 1 
Staining reduced in inter-territorial matrix 2 
Only present in pericellular matrix 3 
Absent 4 
Total Maximum score  13 
 
CELL PROLIFERATION 
Freshly isolated porcine articular chondrocytes were seeded in a 96 well plate at a density of 
10000 cells/cm2 and left attaching overnight in 200 µl of complete medium. One day after 
seeding, the medium was changed and cells were treated for 6 hours with fresh medium 
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containing 100ng/ml of recombinant WNT-3A (R&D system) resuspended in 0.1% BSA w/v in 
PBS or vehicle alone (0.1%BSA w/v in PBS) diluted in complete medium at 37°C (100µl/well). 
Two μCu/μl/cm2 of 3H-thymidine were then added to each well and the incubation was 
prolonged for additional 12 hours. At the end of the incubation the cells were thoroughly 
washed, lysed in trichloracetic acid and the radioactivity (recorded as count per minutes-CPM) 
was measured using a 1900 Liquid Scintillation analyser (Packard). The same procedure was 
repeated at 2 and 3 day time points. 
MICROMASS CULTURE AND ALCIAN BLUE STAINING 
Freshly isolated human articular chondrocytes were resuspended at a density of 2.0x107 
cells/ml in complete medium and micromass cultures were obtained by pipetting 20μl drops of 
cell suspension per each well of a 24 well plate. The cells were left attaching for 3 hours and 
then 1 ml of complete medium was added. Twenty four hours later, micromasses were 
exposed to treatment as described in the individual experiments. Finally, micromasses were 
fixed for 30 minutes in acetone at -20°C and whole-mount stained with alcian blue GS 0.5% as 
described before (De Bari et al., 2001). Proteoglycan content was extracted by incubating the 
micromasses for 6 hours with 6M guanidine HCl and determined measuring the adsorbance of 
the alcian blue at 630nm. Data were then normalized for protein content (determined by BCA 
assay). Absorbance was measured by using a GENios spectrophotometer (Tecan). 
BACTERIAL CULTURES 
AMPLIFICATION OF PLASMID DNA 
PREPARATION OF LB-AGAR PLATES 
After being sterilized, LB-Agar medium was added with Ampicillin or Kanamycin to a final 
concentration of 150µg or 50µg respectively, mixed gently, and approximately 15 ml of 
solution was poured in each individual 300mm bacterial plate. The plates were allowed to set 
for 2 hours at room temperature, inverted, and allowed to dry overnight. The plates were then 
either used immediately, or stored at 4°C. 
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BACTERIAL TRANSFORMATION 
One or more aliquots (30µl each) of thermo-competent DH5α bacteria were defrosted on ice. 
One µg of plasmid DNA was then added to each aliquot and the cells were left resting on ice 
for 30 minutes. For transformation, the bacteria were heat shocked for 20 seconds in a 42°C 
pre-warmed water bath. The bacteria were then put on ice for 2 minutes. Nine hundred 
seventy µl of pre-warmed LB medium were added to each aliquot and the tubes were 
incubated at 37°C for 1 hour at 300 rpm. 
200µl of the transformed cells were then spread under sterile conditions in a pre-warmed 
selective plate and incubated overnight at 37°C. To control for possible contamination of the 
agar plates, one plate was incubated without the addition of bacteria and one plate was 
seeded with untransformed bacteria (heat shocked but without addition of plasmids). As a 
positive control, one plate was spread with a bacterial stock from a previous successful 
transformation. 
The rest of the bacteria was stored until the following day at 4°C. 
PLASMID PURIFICATION 
The day following transformation one or more colonies were removed from the plate by using 
a sterile tip and immersed in 2ml of pre-warmed LB medium containing 0.05-0.15 mg/ml of the 
selective antibiotic solution. The tubes were incubated at 37°C for 14-16 hours with shaking 
(300rpm).  
Following the 14 hours incubation, 1.4ml of each bacterial culture were transferred into one 
Eppendorf tube and centrifuged at maximum speed for 20 seconds. The supernatant was 
discarded and the pellet placed on ice. The bacteria were resuspended by vortexing in 300 µl 
of buffer P1 (Qiagen). Immediately afterwards, 300 µl of buffer P2 (Qiagen) were added and 
the samples were mixed by inversion and put back at room temperature. This resulted in the 
lysis of the cells and release of the amplified plasmid DNA. Finally, 300 µl of buffer P3 (Qiagen) 
were added to each sample and the tubes were placed again on ice for 10-15 minutes. The 
tubes were centrifuged at maximum speed for 10 minutes in a 19°C pre-cooled centrifuge. 
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After spinning, each sample appears to be divided in three parts: a precipitate, a liquid and 
clear part containing the plasmid DNA, and a top precipitated layer. Eight hundred µl of the 
clear part were removed and mixed with 560 µl of ice-cold isopropanol. The tubes were 
incubated on ice for 20 minutes and centrifuged again at 4°C for further 20 minutes to 
precipitate plasmid DNA. The supernatant was discarded and the pellet was washed with 1ml 
of ice-cold 70% v/v ethanol. The samples were eventually centrifuged at maximum speed for 5 
minutes at 4°C. The excess of ethanol was carefully removed without disturbing the pellet. The 
pellet was air dried for 15 minutes at room temperature and resuspended in 20 µl of ultrapure, 
sterile water (Baxter). The concentration of the plasmid DNA was measured by using the 
Nanodrop and adjusted to a final concentration of 1µg/µl. Plasmid stocks were stored at -20°C 
until further use. 
GENERATION AND PRESERVATION OF TRANSFORMED BACTERIAL STOCKS 
Following transformation, the remaining part of the bacterial cell suspension was preserved by 
adding pure sterile glycerol to a final concentration of 10% v/v, mixing, and storing at -80°C. 
This bacterial stock was subsequently used to re-amplify the plasmid DNA. The frozen bacterial 
stock was gently touched with a sterile toothpick, which was subsequently used to streak a 
new LB-agar plate and start a new culture from a single colony. 
TRANSFECTIONS AND REPORTER ASSAY 
Cells were plated into 24 or 6 well well plates and left growing until the attainment of 50-60% 
confluency. The protocols outlined below represent the optimized versions, but different 
proportions of reagents were used in the optimization steps as described in the “Results” 
section. 
LIPOFECTAMINE  
The volumes and the concentrations of the reagents used in the following protocol are for a 
single well of a 24 well plate.  
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Before transfection, the cells were washed once with pre-warmed PBS and the medium 
replaced with antibiotic- and antimycotic-free complete medium. Five hundred µl of medium 
were added to each well. 1µg of plasmid DNA were added to 50ul of Optimem (OM) (Gibco). In 
the meantime, 2ul of Lipofectamine 2000 (Invitrogen) were incubated for 5 minutes in 50ul of 
pre-warm OM (Gibco) and then added to the medium containing the plasmidic DNA. 
Lipofectamine and DNA were incubated together for 20 minutes at room temperature and 
then added to the cells for 8 hours. The medium was replaced with complete medium without 
washing.  
FUGENE AND FUGENE HD 
The volumes and concentrations of the following protocol are sufficient for the transfection of 
a well of a 6-well plate.  
Before transfection the medium of the cells to be transfected was changed with antibiotic- and 
antimycotic-free complete medium (2ml/well). Three µl of Fugene 6 or Fugene HD were mixed 
to 97µl of OM (Gibco) and incubated at RT for 5 minutes. Afterwards, 1 µg of plasmid DNA was 
added to the tube containing the Fugene solution and incubated at room temperature for 15 
minutes. The mix of Fugene and DNA was finally added to the cells. The medium was then 
replaced after 24 hours.  
NUCLEOFECTION (AMAXA) 
Freshly isolated chondrocytes were cultured for 48 hours in complete medium. The culture 
medium was removed from the cells 3 hours before nucleofected and the cells were washed in 
PBS. In order to detach the cells, chondrocytes were incubated for 3 hours at 37°C with a 
solution of complete medium containing 1mg/ml of collagenase P (Roche) and Pronase 
1mg/ml (Roche). After detachment the cells were washed once in PBS and centrifuged for 8-10 
minutes at 200 rpm. This passage was repeated one more time. In the meantime the 
supplemented Human Chondrocyte Nucleofector Solution and the complete medium 
containing 20% FBS were equilibrated to room temperature. One ml of the pre-warmed 
medium was then added to each well of a 6 well plate and left in the incubator. After 
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centrifugation the chondrocytes were re-suspended to a final concentration of 106 cells/100µl 
in the pre-warmed Human Chondrocyte Nucleofector Solution. The samples were finally mixed 
with 2 µg of plasmid and transferred into an Amaxa cuvette, avoiding bubbles. The cells were 
then nucleofected by using program U28 in the Amaxa nucleofector. The cells were then 
added with 500 µl of 20% FBS-containing medium and transferred into the 6 well plate 
previously filled with pre-warmed medium and incubated overnight in standard culture 
conditions.  
ATELOCOLLAGEN:  
Atelocollagen-mediated transfection of chondrocytes was tested with two different conditions.  
1) P0 chondrocytes were resuspended in atelocollagen 0.005%, 0.01%, 0.03%, 0.05%, 0.1% v/v 
diluted in complete medium in presence of 1µg plasmid/10000cells and seeded. 
2) P0 chondrocytes were seeded into plates pre-coated with atelocollagen 1% diluted in 
complete medium and containing 1 µg of plasmidic DNA.  
The medium was changed after 24 hours from transfection. 
TRANSFECTION EFFICIENCY AND CYTOTOXICITY 
The efficiency of transfection was estimated by the proportion of cells that displayed GFP 
fluorescence 24 hours following transfection with the CMV-GFP plasmid. To this end, bright 
field and fluorescent images were taken 24 hours after transfection using a fluorescence 
microscope and fluorescent and non-fluorescent cells were counted in two random fields of 
each well. Transfection efficiency was defined as the percentage of fluorescent to total cells.  
In some experiments the transfection efficiency was determined by FACS analysis as the 
percentage of green fluorescent cells.  
The survival rate was determined by trypan blue exclusion test or by FACS analysis. FACS 
analysis was performed by Dr Fulvio D’Aquisto. In the FACS plot in Fig. 51 and 54, SSH 
represents the granularity of the cells and the FSH the dimension of the cells. Gated dots 
represent the number of cells which identified as viable chondrocytes. 
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REPORTER ASSAY 
In all the reporter assays described in this thesis transfection was performed with 
Lipofectamine as described previously.  
SUPER8XTOP/FOP REPORTER ASSAY 
After reaching 50%-60% confluency, human articular chondrocytes were co-trasfected with 
SUPER8XTopFlash –or its mutagenized form SUPER8XFopFlash- reporter vector (kind gift of 
Prof. Moon, University of Washington, USA), and CMV-Renilla luciferase vector (Promega), in a 
ratio 1:10. The SUPER8XTopFlash plasmid encodes for the Firefly (Photinus pyralis) luciferase 
gene under control of 7 TCF/LEF binding sequences whereas the SUPER8XFOPFlash is the 
control vector for theSUPER8XTOP, containing 6 mutated and not functional TCF/LEF binding 
sequences. The CMV-Renilla plasmid encodes for the Renilla (Renilla reniformis ) luciferase 
gene under control of the CMV promoter. After overnight incubation at 37°C, the medium was 
changed and the cells were incubated for 24 hours with 100ng/ml of recombinant WNT-3A 
(R&D System) diluted in complete medium. In some experiments conditioned medium 
obtained by WNT-3A overexpressing L-cells was also used. The cells were subsequently lysed in 
passive lysis buffer 1X (Promega) for 30 minutes at room temperature under slow agitation 
and then scraped with the help of a pipette tip. Twenty µl of each lysate were successively 
added to 100µl of the Firefly Luciferase Assay Substrate (part of the Dual Luciferase Reporter 
Assay System kit, Promega) and gently mixed. The luminescence was recorded for 20 seconds 
by mean of TD-20/20 Luminometer (Turner Designs). Firefly luciferase luminescence was then 
quenched by adding 100µl of the Stop & Glo reagent (Dual Luciferase Reporter Assay System 
kit, Promega), containing also the substrate for the Renilla luciferase. The activity of renilla 
luciferase was measured with the same parameters used for the Firefly luciferase. Firefly 
luciferase activity was normalised by Renilla luciferase activity and expressed as relative 
luciferase units (RLU).  
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RNA EXTRACTION  
MONOLAYER 
Total RNA was extracted from fully confluent P0 chondrocytes monolayer cells seeded in 
24well plates. After one wash in PBS, the cells were lysed by direct addition of TRIzol reagent 
(Invitrogen) (1ml/well), and each sample was gently sheered with a syringe for five times and 
collected in an Eppendorf tube. After a first centrifugation at 20000g for 10 minutes, the 
supernatant was collected and the debris, if present, discarded. Two hundred µl of chloroform 
were then added to each sample. The samples were mixed thoroughly by shaking for at least 
20 seconds before being incubated on ice for 2 minutes. The samples were centrifuged for 15 
minutes at 10000g. After centrifugation three different phases are distinguishable in the tubes: 
an upper aqueous phase, containing the RNA, an interphase containing genomic DNA and a 
lower phenolic phase containing proteins. The RNA-containing phase was collected, mixed 
with 500µl of ice-cold isopropanol and left on ice for 30 minutes, to allow the precipitation of 
the RNA. If the expected amount of RNA was very low, in order to maximize the RNA yield, 
0.5µl of Glycogen (Boheringer Mannheim GmbH) was added to each sample. The samples 
were centrifuged at maximum speed for 30 minutes at 4°C and the RNA pellet was 
resuspended in 70% v/v ethanol and eventually centrifuged at maximum speed for 5 minutes 
at 4°C. After centrifugation the ethanol was carefully removed and the pellets were allowed to 
air-dry for 15 minutes at room temperature, and subsequently re-dissolved in 4-12µl of 
ultrapure water, depending on the amount of the RNA purified. The concentration of the RNA 
was evaluated by reading the absorbance at 260 nm using a Nanodrop (Nanodrop) 
spectrophotometer and considering that pure RNA will have a 260/280 ratio between 1.8 and 
2.  
IMPLANTS 
To extract RNA from human cartilage implants, cartilage was immediately frozen in liquid 
nitrogen, after the retrieval from the thigh of the CD1nu/nu mice. The implants were then stored 
in liquid nitrogen until the time of the extraction. 
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Before starting the procedure, a mortar and a pestle were thoroughly washed in 0.5% SDS, 
extensively rinsed and left air drying. They were afterwards submerged in liquid nitrogen along 
with a spatula. All the tools were then removed and liquid nitrogen was added to the mortar. 
The frozen cartilage was immediately placed in the liquid nitrogen-containing mortar avoiding 
thawing, and pulverised with the pestle. With the help of the pre-frozen spatula the powder 
was transferred into a vial containing 1ml of TRIzol. To allow a better disaggregation of the 
tissue, the suspension was sheared gently with a syringe and incubated on ice for 15 minutes 
under gentle tilting. The suspension was then moved to an Eppendorf tube and centrifuged at 
maximum speed for 10 minutes. The pellet was discarded and 200µl of chloroform were added 
to the sample which was then incubated on ice for 2 minutes. The tubes were centrifuged for 
15 minutes at 10000g at 4°C and the aqueous phase containing the RNA fraction, collected. 
These were added with an equal volume of phenol in citrate buffer (Invitrogen) pH 4.5, mixed, 
and left 15 minutes on ice. After addition of an equal volume of chloroform:isoamyl alcohol 
24:1, the samples were mixed, incubated on ice for 2 minutes and centrifuged again for 15 
minutes at 10000g. The aqueous phase was collected and extraction with 
phenol/chloroform:isoamyl alcohol 24:1 was repeated once more. After a last separation with 
only chloroform:isoamyl alcohol 24:1, the aqueous phase obtained from the last centrifugation 
was mixed with an equal volume of pre-chilled isopropanol, shaken for at least 20 seconds and 
incubated on ice for 30 minutes. The samples were centrifuged at maximum speed for 40 
minutes at 4°C. The pellet was washed with 70% v/v pre-chilled ethanol, centrifuged again at 
maximum speed for 5 minutes and left air drying for 15 minutes at 4°C. The RNA was 
eventually dissolved in 10µl of RNA-se free water, the RNA concentration measured 
spectrophotometrically using a Nanodrop spectrophotometer and stored at -80°C until further 
use. 
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GENE EXPRESSION ANALYSIS  
Five hundred nanograms of total RNA from each sample were reverse transcribed by using 
Thermoscript Reverse Transcriptase Kit (Invitrogen) with oligo dT primers and quantitative 
polymerase chain reaction (PCR) was performed with hot-start DNA polymerase (Qiagen) in 
the presence of 0.1X SYBR green (Sigma-Aldrich) and 0.2X ROX dye (Invitrogen) by using a 
T7900 HD (Applied Biosystem) machine. For primer sequences see Table 2. 
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TABLE 2 HUMAN PRIMERS 
Gene Sense Antisense Lenght 
β-actin, 5 -CACGGCTGCTTCCAGCTC-3’, 5 -CACAGGACTCCATGCCCAG-3  134bp 
ADAMTS-5 5’- GACCGATGGCACTGAATGTA -3’ 5’- TGTACAGCTGGAGTTGTCTCCT -3’ 145bp 
Aggrecan 5 -GTTGTCATCAGCACCAGCATC-3’, 5 -ACCACACAGTCCTCTCCAGC-3; 509bp 
Axin-2 5’-TACCGGAGGATGCTGAAGGC-3’ 5’-CCACTGGCCGATTCTTCCTT-3’, 345bp 
Col1A1, 5’-GCCCTGTCTGCTTCCTGTAA-3’, 5’-GGTTCAGTTTGGGTTGCTTG-3’, 104bp 
Col2A1 5 -CTGCTCGTCGCCGCTGTCCTT-3’ 5’-AAGGGTCCCAGGTTCTCCATC-3  432bp 
MMP-3 5’-CAACCGTGAGGAAAATCGATGCAG-3’ 5’-CGGCAAGATACAGATTCACGCTCAA-3’ 440bp 
MMP-13 5’-ACGGACCCATACAGTTTGAATACAGC-3’, 5’-CCATTTGTGGTGTGGGAAGTATCATC-3’ 360bp 
PCNA 5’-GGAGAACTTGGAAATGGAAAC-3’ 5’-CTGCATTTAGAGTCAAGACCC-3’ 548bp 
Sox9 5’-GAACGCACATCAAGACGGAG-3’ 5’-TCTCGTTGATTTCGCTGCTC-3’ 631bp 
WNT-3A 5’-CCATCCTCTGCCTCAAATTC-3’ 5’-TGGACAGTGGATATAGCAGCA-3’. 70bp 
FZD1 5’-TTCAGCAGCACATTCTGAGG-3’ 5’-CCTGCACACATTTTCCCTTT-3’ 154bp 
FZD2 5’-TCACGGTCTACATGATCAAA-3’ 5’-GCAACCTAAAAGTGAAATGG-3’ 266bp 
FZD3 5’-GGATGATCAAAGAAGCAAAG-3’ 5’-TTGAGCCGATGAGAACTACT-3’ 186bp 
FZD4 5’-GACTTTGGAAGGAACCTTTT-3’ 5’-TGAAACCCCGTCTCTACTAA-3’ 238bp 
FZD5 5’-GGTTTGGTGCAGGTGAATTT-3’ 5’-CTACAGCATGGGATAGGCACT-3’ 125bp 
FZD6 5’-TTCGGCAGCTCACTAGGATT-3’ 5’-CATCAGAAAATCTTGCCCAA-3’ 190bp 
FZD7 5’-CTGGAGTTCTTTGAAATGTGCT-3’ 5’-AAGGTTAGCTCCCATGATTCTC-3’ 133bp 
FZD8 5’-CGGTTTGGGTATTCTTAATG-3’ 5’-ACAGGGGTAAGCCTCTAAAC-3’ 215bp 
FZD9 5’-AACACAGAGAAGCTGGAGAA-3’ 5’-ACCACCAGTGACATGAAAAT-3’ 251bp 
FZD10 5’-AGAAACCCTTCAGTGCTACA-3’ 5’-AAAGTGTCTCTGCCAACCTA-3’ 205bp 
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PCR CONDITIONS: 
Cycling was preceded by 2 minutes at 50oC and by a first denaturation step at 96oC, which was 
also needed to activate the hot-start polymerase. The cycling conditions were optimized to 
achieve the highest efficiency coupled with the highest specificity as evaluated by the 
generation of a single amplicon of the expected size on agarose gel electrophoresis. 
Cycling conditions: 
COL2A1, Aggrecan: 2 steps 68 (96°C 30’’, 68°C 1’30’’, 40 cycles) 
COL1A1: 2 steps 60 (96°C 30’’, 60°C 1’30’’, 40 cycles) 
All the other primers: 3 steps 55 (96°C 30’’, 55°C 30’’, 72°C 1’) 
 
At the end of the cycling, a melting curve was performed from 90 until 72 degrees. Comparing 
the melting profile of the positive control (which was also checked for size by agarose gel 
electrophoresis) with that of the test wells helped identifying individual wells in which non-
specific amplification had occurred. Every sample and standard was run in triplicate and a 
water control was used to check for reagents contamination. 
Gene expression was calculated using a standard curve generated with a positive control or a 
specific PCR product diluted 1:1, 1:32, 1:1000 and water control. 
The expression level of each gene was normalized for the correspondent one of β-actin. The Ct 
values of β-actin of all the samples were all between 18 and 20. No variation of β-actin values 
were noticed between treated and not-treated samples. 
SDS-PAGE AND WESTERN BLOTTING  
After treatment, P0 adult human articular chondrocytes (AHAC) cells seeded into 6 well plates 
well plate were washed once in ice-cold PBS containing phosphatase and protease inhibitors 
(Roche).  
Total cell extracts were obtained by scraping the cells in 100µl of extraction buffer and leaving 
the lysates on ice for 30 minutes in total, vortexing the samples every 10 minutes. Protein 
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concentration of the samples was determined by BCA assay (Pierce). A total of 60µg of protein 
lysate per sample were added to 10 µl of Laemmli buffer 5X and the volume was adjusted up 
to 50µl with sterile PBS.  
45 µl of each sample were loaded into 10% v/v Tris-Glycine pre-cast gel (Invitrogen) and run at 
150V until the front dye reaches the bottom of the gel. The gels were then blotted by using i-
Blot system (Invitrogen), a semi-dry blotting system allowing the transfer of the proteins from 
the polyacrilamide gels to nitrocellulose membranes. 
 
β-catenin staining: the membranes were blocked in 5% non-fat milk prepared in PBS/0.1% v/v 
Tween (milk) for at least 3 hours at RT. The membranes were then incubated overnight at 4°C 
with anti β-catenin antibody (1:1000, Cell Signaling) diluted in milk, under slow agitation.  
CaMKII and pT286CaMKII staining: the membranes were blocked in 5% BSA prepared in 
PBS/0.1% TWEEN (blocking solution) for at least 3h at RT. The membranes were then 
incubated overnight at 4°C with anti CaMKII antibody (1:2000, Abcam) or anti p286CaMKII 
(1:1000, Cell signalling) diluted in the blocking solution, under slow agitation.  
 
The primary antibody was then removed and the membranes washed three times 
consecutively in PBS/TWEEN 0.1% (washing buffer). After these three initial washes the 
membranes were washed other 4 times every 15 minutes for 1 hour in total, under slow 
agitation. Subsequently, the membranes were incubated for 45 minutes at RT with the 
appropriate HRP-conjugated secondary antibody (goat anti-rabbit or goat anti-mouse from 
Santa Cruz) diluted 1:2000 in milk. The samples were washed again as after the primary 
antibody, and incubated for 1 minute and 30 seconds in the dark with home-made 
chemiluminescent solution. 
 
 
 
Materials and Methods 
 69 
PHOSPHO CAMKII IMMUNOFLUORESCENCE 
For immunofluorescence, AHAC were seeded (104 cells/cm2) on chamber slides (Lab-Tek) and 
treated for 24 hours with 100 ng/ml of recombinant WNT-3A in combination with 10μM KN92 
or KN93 (Calbiochem). The cells were then washed in PBS and fixed in 4% buffered PFA (pH 
7.4) for 5 minutes at room temperature. Auto-fluorescence was quenched by incubating the 
section twice in 50mM NH4Cl for 10 minutes. After 1 hour blocking in FBS diluted 1:5 plus 0.2% 
Triton X, the sections were incubated overnight at 4°C with anti phospho-CaMKII rabbit 
polyclonal antibody (Cell Signalling) or rabbit IgG (Dako) as negative control, both diluted 1:100 
in blocking solution. After washing twice for 10 minutes each in PBS/0.2%Triton X (washing 
solution), the cells were incubated with cy3-conjugated goat anti-rabbit antibody 1:300 
(Jackson ImmunoResearch Laboratories) for 1 hour. Slides were mounted in Mowiol 
(Calbiochem, Merck Biosciences Ltd) and images were taken with an Olympus BX61 
microscope by using 40X magnification/0.85 of numerical aperture. Images were acquired with 
a fluorescence microscope (Olympus BX61) by using an uplan Fluo 40x NA 0.85 objective. After 
acquisition and densitometric analysis (see below), the contrast of the images was enhanced 
for best graphic rendering using Adobe Photoshop 7.0, all with the same parameters, without 
altering relationship of target to control images. The fluorescence intensity was measured by 
using Image J software on the original photographs. The average pixel intensity profile (y-axis: 
0=black, 255=white) was plotted over a linear length of a whole cell. The mean nuclear and 
cytoplasmic fluorescence intensity, obtained by the plot profile as shown in Fig. 35, were 
generated by analysing 40 cells per field in duplicate for each condition.  
 
HIS-TAG DETECTION BY IMMUNOFLUORESCENCE 
For the detection of the His Tag in the cartilage implants retrieved after the co-injection of 
AHAC with Cos7 cells transfected with a His-tagged vector encoding for granulocyte 
chemotactic protein 2/chemokine alpha 3 (GCP2/CKA) (pGCP2MycHis, map in Fig. 14), sections 
were equilibrated in 0.02% HCl for 15 minutes then digested in 0.25 mg/ml of pepsin (Sigma) in 
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0.02% v/v HCl for 45 minutes at 37°C, washed in water and allowed to air dry for 20 minutes. 
Next, the sections were post-fixed in 4% PFA for 10 minutes at room temperature, and washed 
twice with PBST (5 minutes washes). The endogenous peroxidase activity was quenched by 
incubating the sections with 10% v/v H2O2 for 15 minutes. The sections were blocked in Protein 
Blocking Solution (Dako) for 1 hour at room temperature, blotted, and incubated overnight at 
4°C with the primary antibody Goat polyclonal to 6x His Tag HRP diluted to a final 
concentration of 4mg/ml (Abcam) in the protein Blocking Solution (Dako). Sections were then 
washed three times in PBST and developed with liquid DAB Substrate Chromogen System 
(DAB) as peroxidase substrate (BDH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: GCP2 (CKA) MycHis tagged encoding plasmid 
 
CALCIUM MOBILIZATION ASSAY 
P0 AHAC were seeded at a density of 6000cells/well into a 96 well plate. One day after seeding 
the cells were labelled for 30 minutes at RT and for 30 minutes at 37°C with 50µl of Fluo-4-
Direct kit (Invitrogen) solution containing 2.5mM Probenecid and were subjected to 
treatments with growth factors or inhibitors as indicated for individual experiments. After 
CKA3 into pCDNA3 mycHis A espression vector
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treatments, the fluorescence emitted by the cells (excitation wavelength 494 nm, emission 
wavelength 516 nm) was recorded using a Fluo-Star Galaxy fluorimeter. The fluorescence was 
expressed as Relative Fluorescence Units (RFU). 
ECTOPIC CARTILAGE FORMATION ASSAY 
This assay measures the capacity of cells to form ectopic stable cartilage in vivo and was 
performed as previously described (Dell'Accio et al., 2001). Five million cells per injection were 
used. Cells were washed twice in PBS and resuspended in aliquots of 5X106 cells in 50μl of PBS 
and injected in the posterior compartment of the thigh of female CD1nu/nu mice. After 14 days 
the mice were killed and the implants carefully dissected. Each implant was measured for wet 
weight and cut in half along the longest axis. One half was processed for total RNA extraction, 
and the other fixed and embedded in Optimal Cutting Temperature (OCT) or paraffin for 
histological examination. The sample orientation was arranged in such a way that the first 
section went through the cleavage plane of the explants and represented the cross-sectional 
largest area. 
GENERATION OF GROWTH ARRESTED CELL LINES FOR GENE DELIVERY 
In some experiments, chondrocytes were co-injected with growth arrested cell lines-Cos7 
(monkey kidney fibroblasts) and L-cells (murine skin fibroblasts) overexpressing foreign genes. 
To induce growth arrest, the cells were cultured until they reached 80% confluency. 7.5 µg/ml 
(for L-cells) or 5 µg/ml (for Cos7 cells) of mitomicyn C where added to the culture medium and 
the cells returned to the incubator. After two hours, the cells were washed twice in PBS, 
counted and checked for viability. The cells were then either replated to control for efficacy of 
growth arrest, or used for co-implantation in a proportion of 1/10 growth arrested 
cells/chondrocytes.  
 
 
 
Materials and Methods 
 72 
HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
PARAFFIN EMBEDDING 
a) Samples were fixed overnight in freshly made 4% buffered PFA o/n at 4°C.  
b) The samples were dehydrated through a gradient of ethanol, xylene and paraffin.  
c) The samples were embedded in paraffin and stored at RT until needed. 
d) Sectioning was performed with 5μm slices. The sample number was recorded to allow 
serial staining. 
OCT EMBEDDING 
a) A drop of OCT was placed in a foil mould.  
b) The sample was added, and oriented as required, and then covered completely with 
OCT.  
c) A 6 well plate filled with isopentane (2-methyl butane) was placed in a box filled with 
liquid nitrogen, bringing the isopentane at its freezing point (-160°C).  
d) The cylinder with the embedded sample was then placed within the ice-cold 
isopentane, until completely frozen.  
e) Blocks were stored at -80°C in 24 well plates until needed.  
f) The OCT blocks were sectioned serially using a cryostat with 7 μm-thick sections. All 
sections were serially numbered to facilitate serial staining.  
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PREPARATION OF PARAFFIN SECTIONS 
a) Sections were heated at 55°C for 15 minutes and immediately immersed in xylene. 
b) Sections were deparaffinized through 2 serial passages (5 minutes each) in xylene, and 2 
passages in 100% ethanol (5 minutes each). 
c) Sections were air dried for 20 minutes. 
PREPARATION OF FROZEN SECTIONS 
a) The OCT blocks were equilibrated overnight at -20oC 
b) The cryostat was equilibrated with a room temperature of -18°C and a sample 
temperature of -20°C 
c) Sectioning was performed at an interval of 7μm 
d) Sections were air-dried overnight and then stored at -20oC until further use 
e) Sections were thawed and air dried at room temperature for 30 minutes 
f) For some applications including immunohistochemistry, sections were post fixed with 
one drop of freshly made 4% PFA for 5 minutes, and rinsed in PBS. 
HAEMATOXYLIN AND EOSIN (H&E) STAINING  
1) Frozen sections were gradually rehydrated in descending grades of ethanol (100%, 
70% and 50% ethanol (5 minutes each)  
2) Sections were washed in distilled water for 5 minutes 
3) The sections were stained for 5 minutes in Mayer’s hematoxylin (BDH) 
4) The slides were then washed again in water and placed in Eosin (BDH) for 1 minute 
5) The slides were washed again and dehydrated in ascending grades of ethanol (50%, 
70% and 100% for 5 minutes each 
6) Two passages in xylene (5 minutes each) and mounted with DEPEX. 
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TOLUIDINE BLUE STAINING 
1) The slides were deparaffinised in xylene (2X5minutes) and 100% ethanol (2X5minutes) 
2) The sections were washed in distilled water for 5 minutes 
3) One drop of toluidine blue prepared in acetate buffer (pH 4.0) was put on each section 
for a maximum of 30 seconds. The excess of dye was removed by washing the slides in 
water and the sections were left air drying. 
4) The sections were then differentiated in ethanol 100% ethanol (2X5minutes), then in 
xylene (2X5 minutes) and mounted with DEPEX. 
 
SAFRANIN O STAINING 
1) The slides were deparaffinised in xylene (2X5 minutes) and 100% ethanol (2X5 
minutes)  
2) The sections were washed for 5 minutes in  and immersed in safranin O (SO) 0.2% w/v 
for 13 minutes.  
3) The sections were rinsed thoroughly in distilled water (2X2 minutes)  
4) The sections were then differentiated in ethanol 100% ethanol (2X5minutes), then in 
xylene (2X5 minutes) and mounted with DEPEX. 
IMAGES AND DIGITAL PHOTOGRAPHY 
Images were taken with an Olympus BX61 microscope. Images were acquired at 22°C, by using 
an Olympus F-View II (SIS) camera and Cell P software.  
For fluorescent images, the acquisition parameters were set using the positive and negative 
control sections to achieve the maximum sensitivity and specificity as described below and 
were then used constant for the acquisition of all images. 
a) Autogain off 
b) Setting exposure time. The negative control (non-immune IgG) was placed in on the 
microscope and the exposure time set and fixed in such a way that the background 
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fluorescence was barely visible or not visible at all. This same exposure time was used 
to acquire all images. 
c) Gain setting. The gain parameter was set using the section, within the experiment, 
with the strongest fluorescence. The upper limit was then set so that the brightest 
point was nearly completely white, but with a value ≤ 225, and then kept constant for 
all images. This allowed preventing saturation and consequent loss of sensitivity. 
IMAGE ANALYSIS 
Image analysis was performed using image J software. Original black and white images were 
used to quantify fluorescence. Original color images were used to quantify morphological 
parameters and safranin O staining. 
AREA DETERMINATION 
5 non-consecutive sections were chosen through the centre of the explants covering a total of 
350µm in thickness. These sections therefore represented the maximum cross-sectional area. 
The implant area was manually drawn, eliminating the residual skeletal muscle left attached. 
After calibration, the area of the implant in each section was determined and the value 
averaged. 
SAFRANIN O INTENSITY 
The sample area identified in the previous paragraph was saved as a mask. The pictured were 
transformed in grayscale. The average gray value within each mask was averaged and 
represented the intensity of safranin O staining. 
FLUORESCENCE INTENSITY AND CELLULAR DISTRIBUTION (CAMKII IMMUNOSTAINING) 
Fluorescent images were acquired as described above. For each cell analysed a line along the 
maximum axis (Fig. 32) was drawn. The grayscale values along the line were plotted with a 
histogram using Image J. 
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The area under the curve was calculated and represented the total fluorescence. The area 
under the curve relative to the segment corresponding to the nucleus was also calculated and 
represented the nuclear fluorescence (Fig. 35). 
STATISTICAL ANALYSIS 
Parametric data were compared with student T-test. For multiple comparisons we used 
ANOVA analysis, with Dunnet post-test. Data in Fig. 33B were analysed with Kruskal Wallis with 
Dunns post-test. P values less than 0.05 were considered significant. *, p<0.05; **, p<0.005; 
***, p<0.0005. In the graphs values are expressed as mean±SEM. 
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BUFFERS AND MEDIA 
COMPLETE MEDIUM 
1% antibiotic-antimycotic solution 
1% NaPyr 
10% serum 
FREEZING MEDIUM 
7.5ml FBS 
5ml DMSO 
Top to 25 ml with complete medium 
Sterilize by filtration 
LB MEDIUM 
10g tryptone 
5g yeast extract 
10g NaCl 
LB-AGAR 
10g tryptone 
5g yeast extract 
10g NaCl 
15g AGAR 
Autoclave to solubilize 
SDS-PAGE 
EXTRACTION BUFFER 
10 mM HEPES 
1.5 mM MgCl2 
10 mM KCl 
0.5 mM DTT 
0.05% NP40  
pH 7.9 
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TRIS-GLYCINE RUNNING BUFFER 
25mM Trizma-Base 
192mM Glycine 
0.1% SDS 
pH8.3 
LAEMMLI BUFFER 
63mM Tris HCl 
10% Glycerol 
2% SDS 
0.0025% Bromophenol blue 
pH 6.8 
BLOCKING SOLUTION (BETA-CATENIN) 
5% non-fat milk 
0.1% TWEEN 
PBS 
BLOCKING SOLUTION (CAMKII OR PCAMKII) 
5% non-fat milk 
0.1% TWEEN 
TBS 
WASHING SOLUTION 
0.1% TWEEN 
PBS/TBS 
ECL 
Solution 1 
1ml of luminol stock (250mM luminol in DMSO (0.88g/20ml)) 
0.44ml p-coumaric acid stock (0.29g/20ml) 
10ml 1M Tris Base (pH 8.5) 
Make up to 100ml with distilled water 
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Solution 2 
64µl 30% H2O2 
10ml Tris Base (pH 8.5) 
Make up to 100ml with distilled water 
 
Mix 1:1 and add for 1’30” on the nitrocellulose membrane prior developing. 
 
ACETATE BUFFER 
Stock solutions: 
Stock A: 0.2M acetic acid 
(1.2 cm3 glacial acetic acid in 100 cm3 of distilled water) 
Stock B: 0.2M sodium acetate 
(1.64g sodium acetate anhydrous in 100 cm3 of distilled water) 
For toluidine blue solution 
41 cm3 of Stock A + 9cm3 of Stock B made up 100cm3 with distilled water (final solution=pH 
4.0) 
TOLUIDINE BLUE 
Add 0.2g toluidine blue powder to 100ml of the acetate buffer and filter. 
Leave resting at RT for at least 1 week. 
SAFRANIN O 
0.2% SO in 0.2M glacial acetic acid in distilled water 
HAEMATOXYLIN 
For 2 liters 
 2g Haematoxylin powder 
 100g Aluminium Potassium Sulphate 
 0.4g Sodium Iodate 
Heat at 85°C for 1-2 hours 
Once dissolved add: 
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 1g Citric Acid 
 100g Choral Hydrate 
Heat again at 85ºC for 1-2 hours 
EOSIN 
Dissolve 10g of Eosin Y in 1l of distilled water on a warm stirrer plate. Filter the solution prior 
the use. 
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BIOLOGICAL EFFECTS OF WNT-3A TREATMENT ON ARTICULAR 
CHONDROCYTES IN VITRO 
EXPRESSION OF WNT-3A AND FZD RECEPTORS IN HUMAN ARTICULAR CHONDROCYTES 
To test the biological effect of the activation of the Wnt/β -catenin pathway in human 
articular chondrocytes, we chose to stimulate these cells with WNT-3A. WNT-3A is a 
prototypical, well characterized activator of the β -catenin dependent canonical 
pathway (Shimizu et al., 1997) which an established role in arthritis (Nakamura et al., 
2005). Confirming such involvement, we detected WNT-3A in normal articular cartilage and 
we discovered that its mRNA expression was down-regulated in OA (Fig. 15).  
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Figure 15 :WNT-3A mRNA expression in human articular cartilage 
WNT-3A mRNA expression in human articular cartilage. Normal cartilage was removed from the knee of 
an amputee patient (n=1). Preserved cartilage was defined by a Mankin score ≤ 4; damaged cartilage 
had a Mankin score ≥ 6 (n=3). Preserved and damaged cartilage were removed from different areas of 
the tissue taken from the same patient. Gene expression values were obtained by Q-PCR and 
normalized for the housekeeping gene β-actin. The values are expressed as mean±SEM. The values are 
not statistically different in a significant way. 
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Before evaluating the effect of WNT-3A stimulation I also checked for the expression 
of all the Frizzled (FZD) receptors known to modulate canonical and non-canonical 
pathways (Fig. 16). 
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Figure 16: Gene expression analysis of FZD receptors in human cartilage explants and P0 chondrocytes 
(A-C) Gene expression levels of FZD receptors in human cartilage explants and P0 chondrocytes. (A) 
Expression levels of FZD receptors in P0 chondrocytes were assessed by semi-quantitative PCR 
(40cycles). Each band correspond to cDNA extracted from a different donor. (B) The intensity of the 
bands was measured using densitometry by Image J software and then normalized for the intensity of β-
actin (25 cycles). (C) Expression levels in human cartilage explants were obtained by a microarray 
analysis in cartilage explants (Dell'Accio et al., 2008). RDU= Relative Densitometry Units.  
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All FZD receptors were expressed at mRNA levels both in articular chondrocytes 
cultured in monolayer and in human cartilage explants (Fig. 16). Therefore, articular 
chondrocytes maintain in vitro the expression of FZD receptors and the capacity to 
respond to Wnts. 
WNT-3A PROMOTES ARTICULAR CHONDROCYTE PROLIFERATION 
I then started to investigate the function of this ligand on the proliferation, 
differentiation, and extracellular matrix production of articular chondrocytes, 
because all these biological outcomes are relevant to cartilage homeostasis.  
Treatment of primary porcine articular chondrocytes with 100 ng/ml of r ecombinant 
WNT-3A over a three day time course resulted in a statistically significant increase of 
cell proliferation compared to vehicle control (Fig. 17A). The proliferative effect of WNT-
3A was confirmed in human articular chondrocytes, where the proliferation marker PCNA was 
up-regulated 24 hours after stimulation with WNT-3A (Fig. 17B). 
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Figure 17: WNT-3A promotes articular chondrocyte proliferation 
(A) Porcine articular chondrocytes were treated with 100ng/ml of recombinant WNT-3A or vehicle for 
three days. Incorporation of tritiated thymidine was recorded every 24 hours and the counts plotted 
(n=6 for each time point). (B) WNT-3A promotes up-regulation of the proliferation marker gene PCNA in 
AHAC. P0 AHAC were treated for 24 hours with 100 ng/ml of recombinant WNT-3A and PCNA gene 
expression levels were analyzed by Q-PCR and normalized for β-actin (n=4). Statistical analysis was 
performed with unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 88 
WNT-3A PROMOTES ARTICULAR CHONDROCYTE DE-DIFFERENTIATION 
WNT-3A has been shown to delay chondrogenesis in mesenchymal stem cells and to promote 
chondrocyte de-differentiation in articular chondrocytes (Ryu et al., 2002;Reinhold et al., 
2006). To test the effect of WNT-3A stimulation in my system, I compared the expression of 
chondrocyte-lineage markers by confluent primary AHAC treated with either WNT-3A or 
vehicle control. COL2A1, Aggrecan, and SOX9 mRNA were statistically significantly down-
regulated following WNT-3A treatment (Fig. 18). In contrast with previous data (Yuasa et al., 
2008), the chondrocyte hypertrophy marker MMP13 was also down-regulated. Other genes 
relevant to cartilage homeostasis/biology including COL1A1, MMP-3, and ADAMTS5 (Goldring, 
2006) were unchanged (Fig. 18). 
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Figure 18: WNT-3A promotes articular chondrocyte de-differentiation 
WNT-3A induced down-regulation of the differentiation markers COL2A1, Aggrecan, SOX9 and MMP13, 
as evaluated by Q-PCR (n=6, 3 donors, 2 samples/donor). Gene expression values are reported as 
percentage of up- or down-regulation compared to control (100%-dotted line in the graph). Statistical 
analysis was performed by paired T-test. 
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The main function of articular chondrocytes is the production of a specialized extracellular 
matrix rich in highly sulphated GAGs, which provide the elastic biomechanical properties 
required for motion and weight bearing. Therefore, to test whether WNT-3A affected this 
important function of chondrocytes, I took advantage of the capacity of chondrocytes to 
produce large amounts of such matrix when cultured in 3D micromasses.  
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Figure 19: WNT-3A decreases ECM deposition in AHAC micromasses 
P0 Chondrocyte micromasses were stimulated for four days with 100ng/ml of recombinant WNT-3A. 
The micromasses were then fixed in methanol and stained overnight with alcian blue. Following 
extraction in 6M guanidine, the amount of the Alcian blue was quantified by spectrophotometric 
measurement at 630nm (n=4). Statistical analysis was performed by unpaired t-test. 
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Treatment of human primary AHAC micromasses with 100ng/ml of WNT-3A for 4 days induced 
a statistically significant decrease in the accumulation of highly sulphated GAGs, as evaluated 
by Alcian Blue staining and spectrophotometric quantitation (Fig. 19). 
On mesenchymal stem cell micromasses, the decrease of proteoglycan content due to WNT-3A 
stimulation was shown to be an irreversible process (ten Berge et al., 2008). To test if this was 
true also in micromasses obtained from fully differentiated cells, I stimulated AHAC 
micromasses for four days with WNT-3A and then I withdrew the stimulus for additional 4 
days. 
The proteoglycan content of micromasses in which the stimulus was withdrawn was similar to 
the ones in which WNT-3A stimulation was prolonged for 8 days; this shows that the biological 
effect of WNT-3A is permanent and irreversible also in this biological system (Fig. 20) 
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Figure 20: Articular chondrocyte de-differentiation promoted by WNT-3A is irreversible 
Chondrocyte micromasses were stimulated for 8 days with conditioned medium obtained from L-cells 
overexpressing WNT-3A (diluted as described in the “Appendix 2” session) with control-medium. A 
separate group was stimulated with WNT-3A conditioned medium for 4 days before withdrawing the 
stimulus for other 4 days. The micromasses were stained with alcian blue overnight and proteoglycan 
content measured after guanidine extraction. n=4 for each condition. Statistical analysis was performed 
by unpaired t-test. 
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These data are largely in keeping with previous literature: WNT-3A treatment promoted 
human articular chondrocyte proliferation, but also induced down-regulation of the 
chondrocyte phenotypic marker genes COL2A1, AGGRECAN, and SOX9. In addition, WNT-3A-
stimulation decreases the expression of the hypertrophic marker gene MMP13. 
WNT-3A treatment also decreased the accumulation of GAGs in chondrocyte micromasses. 
From this experiment we cannot determine if this is due to a decreased synthesis or to an 
increased catabolic activity. On the basis of the gene expression analysis data, we prefer the 
first hypothesis, since the expression of Aggrecan and MMP13 mRNA is reduced upon WNT-3A 
stimulation as well as MMP13 expression. However, both decreased synthesis and increased 
metalloproteinase activity have been demonstrated in the previous literature (Yuasa et al., 
2008). To better understanding how WNT-3A influence GAGs content, 35S-incorporation and 
metalloproteinase activity should be monitored. 
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BIOLOGICAL EFFECTS OF WNT-3A TREATMENT ON ARTICULAR 
CHONDROCYTES IN VIVO 
To confirm the validity of the biological effects of WNT-3A in an in vivo system, we used a well-
established model that measures the capacity of chondrocytes to form ectopic stable hyaline-
like cartilage when implanted intramuscularly in nude mice (Dell'Accio et al., 2001). The 
ectopic cartilage formation assay has been proven to be an accurate and reproducible tool to 
assess if the chondrocytes have lost their phenotypic stability (Dell'Accio et al., 2001). 
Following serial culture expansion, chondrocytes irreversibly lose their phenotype and the 
ability to form cartilage in vivo, although they still can re-express COL2A1 or Aggrecan when 
cultured in anchorage independent conditions (e.g. in agarose)(Benya and Shaffer, 1982). The 
assay was also validated to predict the successful outcome of autologous chondrocyte 
transplantation (ACI) in a goat model (Dell'Accio et al., 2003b) and in human (Saris et al., 
2009;Saris et al., 2008). 
To provide a constant supply of WNT-3A during the cartilage implant formation in vivo with 
minimal manipulation of the chondrocytes, we set up a cell-delivery system based on the co-
injection of the articular chondrocytes with growth-arrested L-cells overexpressing WNT-3A or 
untransfected, growth arrested, L-cells as control. We then performed a thorough validation of 
this method demonstrating effective growth arrest, that growth arrested L-cells retain the 
capacity to stably express and secrete biologically active WNT-3A for at least 2 weeks, and that 
growth arrested cells persist alive when co-implanted in vivo. The data relative to such 
validation are quite large, and therefore we have reported them as a methodological chapter 
in "Appendix 3" at the end of this thesis. 
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We performed the ectopic cartilage formation assay in nude mice by co-injecting 5X106 freshly 
isolated porcine chondrocytes with 5X105 L-WNT3-A cells or wild type L-cells as control. We 
performed 12 co-implantations per group. Two weeks following implantation, the mice were 
killed, the explants carefully dissected and measured for wet weight. Subsequently the 
explants were fixed, cut through their major axis, sectioned, and the sections through the 
centre were utilized for histomorphometrical assessment as described in detail in the 
“Materials and Methods” section.  
To compare the degree of chondrocytic differentiation and extracellular matrix production in 
the two groups of implants we used Safranin O staining. The staining was statistically 
significantly weaker in the implants obtained by the co-injection of the chondrocytes with the 
WNT-3A overexpressing L-cells (Fig. 21A-F). 
The wet weight and the cross-sectional area of the cartilage implants retrieved from mice 
injected with chondrocytes plus L-WNT-3A cells was statistically significantly higher compared 
to that of implants obtained from chondrocytes co-implanted with control L-cells (Fig. 22A-B), 
this suggesting a higher degree of chondrocyte proliferation in the implants subjected to WNT-
3A stimulation. 
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Figure 21: WNT-3A promotes de-differentiation of articular chondrocytes in vivo 
Safranin O staining of cartilage implants obtained by the co-injection of porcine articular cartilage with 
L-cells (A-B) or L-WNT-3A cells (C-D) in nude mice. (E-F) Cartilage implants obtained from the co-
injection with L-WNT-3A cells are less differentiated as shown by decreased safranin O staining. Two 
different parameters were evaluated by using image J software: the average of the total safranin O 
staining in the implant (E) or the percentage of the total area reaching an intensity of staining equal to a 
fixed thresholded value (F). Grayscale digital images from safranin O (SO) staining were used to calculate 
and compare the intensity of the staining (12 implants per conditions were evaluated; 1 slide per 
implant was stained and analysed). M=muscle; I=Implant. Unpaired T-test was used for statistical 
evaluation. 
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Figure 22: WNT-3A promotes the formation of larger cartilage explants in vivo. 
(A) Cartilage implants retrieved from nude mice co-injected with porcine articular chondrocytes and L-
WNT-3A cells had a statistically significant higher wet weight. (B) After removal from the muscle of the 
nude mouse, the cartilage implants were cut in two parts through the longitudinal axis and paraffin 
embedded. Implants were stained with safranin O and the surface area calculated with Image J software 
excluding any residual murine muscular tissue (12 implants per conditions were evaluated). The 
unpaired T-test was used for statistical evaluation. 
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Similar results were obtained with primary AHAC (Fig. 23), thereby confirming that this 
biological outcome is conserved across mammals. 
 
Figure 23: WNT-3A promotes the formation of larger more de-differented human articular 
chondrocyte implants in vivo 
A-E) Cartilage implants retrieved from nude mice co-injected with human articular chondrocytes and L-
WNT-3A cells had a higher wet weight and a weaker SO staining in comparison to control implants. After 
removal from the muscle of the nude mouse, the cartilage implants were cut in two parts through the 
longitudinal axis and paraffin embedded. Cartilage implants obtained from the co-injection with L-WNT-
3A cells are less differentiated as shown by decreased safranin O staining. Two different parameters 
were evaluated by using image J software: the average of the total safranin O staining in the implant (D) 
or the percentage of the total area reaching an intensity of staining equal to a fixed thresholded value. 
(E) Grayscale digital images from safranin O (SO) staining were used to calculate and compare the 
intensity of the staining (3 implants per condition were analysed; five sections per implant were 
averaged).  
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The chimeric nature of these implants also allowed gene expression analysis selectively for the 
chondrocytes using human specific primers. The mRNA levels of the proliferation marker gene 
PCNA were increased, whereas COL2A1, Aggrecan and Sox9 levels were decreased, even 
though this did not reach statistical significance, probably due to the small sample size (n=3 
per condition) of this experiment (Fig. 24). 
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Figure 24: WNT-3A promotes human chondrocyte de-differentiation in vivo 
A-D) RNA was extracted by the cartilage implants retrieved from the nude mice. After retrotranscription, 
the levels of PCNA, COL2A1, Aggrecan and SOX9 mRNA were measured by real time PCR. n=3 for each 
condition. 
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Together, these data show that co-injection of porcine or human articular chondrocytes with L-
cells over-expressing WNT-3A results in an increased proliferation of these cells and in their 
de-differentiation. These results confirm the biological effect of WNT-3A seen in vitro in an in 
vivo system of high clinical relevance.  
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WNT-3A ACTIVATES THE CANONICAL PATHWAY IN HUMAN ARTICULAR 
CHONDROCYTES 
Having confirmed that WNT-3A promotes proliferation and de-differentiation, we decided to 
determine the molecular mechanisms of these effects. WNT-3A is known to activate the 
Wnt/β-catenin pathway in a variety of cells. We therefore set out to confirm the activation of 
this pathway by WNT-3A in AHAC. Treatment with 100 ng/ml recombinant WNT-3A resulted in 
accumulation of β-catenin (Fig. 25), activation of the SUPER8XTOPFlash reporter assay (Fig. 
26A), and a 250 fold up-regulation of the endogenous target gene AXIN2 (Yan et al., 2001)(Fig. 
26B), indicative of activation of the β-catenin-dependent canonical pathway. 
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Figure 25: WNT-3A causes accumulation of β catenin in AHAC  
Western blotting for β-catenin in the cytoplasmic fraction of AHAC treated for 24 hours with 100 ng/ml 
of recombinant WNT-3A or vehicle control. 
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Figure 26: WNT-3A activates the LEF/TCF-dependent transcription in AHAC.  
(A) Twenty four hours stimulation of AHAC with 100ng/ml of recombinant WNT-3A activated the 
SUPER8XTOPFlash reporter assay in P0 AHAC (n=3). (B) WNT-3A up-regulated the expression of the 
endogenous Wnt-canonical target gene AXIN2 in AHAC as evaluated by Q-PCR. Values were normalized 
for the housekeeping gene β-actin. n=6 (3 donors; 2 samples/donor). Data were analysed with unpaired 
T-test. 
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DKK1 INHIBITS THE ACTIVATION OF THE CANONICAL PATHWAY PROMOTED 
BY WNT-3A BUT NOT WNT-3A-INDUCED DE-DIFFERENTIATION 
To confirm that the observed AHAC phenotypic changes were due to the activation of the 
canonical pathway, primary AHAC were treated with either 100 ng/ml WNT-3A alone or in 
combination with 100 ng/ml of recombinant DKK1, which specifically inhibits the β-catenin-
dependent pathway by binding to LRP co-receptors and preventing their association with FZDs 
(Mao et al., 2001). Co-treatment with DKK1 reverted the WNT-3A-induced up-regulation of 
AXIN2, PCNA and MMP13 (Fig. 27A-C), confirming the inhibition of the canonical pathway.  
Surprisingly however, DKK1 failed to rescue the down-regulation of COL2A1, Aggrecan, and 
SOX9 mRNA in the samples co-treated with WNT-3A and DKK1 (Fig. 28A-C). 
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Figure 27: DKK1 inhibits the activation of the Wnt-β-catenin pathway induced by WNT-3A and rescues 
its effects on proliferation and MMP13 expression. 
A-C) Primary AHAC were treated for 24 hours with 100 ng/ml of recombinant WNT-3A alone or in 
combination with DKK1, and were subjected to gene expression analysis by PCR. Blockade of the Wnt-
canonical pathway by DKK1 rescued the modulation of AXIN2, PCNA, and MMP13 mRNA. n=6 (3 donors, 
2 samples/donor). Data were analysed by unpaired T-test. Gene expression levels are expressed as 
percentage of the vehicle-treated cells. 
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Figure 28: Figure DKK1 does not rescue the loss of chondrocyte phenotype induced by WNT-3A 
A-C) Primary AHAC were treated for 24 hours with 100 ng/ml of recombinant WNT-3A alone or in 
combination with DKK1, and were subjected to gene expression analysis by PCR. Blockade of the Wnt-
canonical pathway by DKK1 did not rescue the down-regulation of COL2A1, Aggrecan, and SOX9 
promoted by WNT-3A. n=6 (3 donors, 2 samples/donor). Data were analysed by unpaired T-test. Gene 
expression values are expressed as percentage of the vehicle-treated cells. 
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To investigate whether this was due to excessive, exogenous WNT-3A stimulation, we 
investigated if treatment with DKK1 alone, in the absence of exogenous WNT-3A, modified the 
phenotype of AHAC. Strikingly, treatment of AHAC with DKK1 in the absence of WNT-3A, 
promoted by itself a down-regulation of COL2A1 and Aggrecan, similar to that induced by 
WNT-3A, and up-regulation of MMP13 although, as expected, it did reduce AXIN2 and PCNA 
mRNA expression (Fig. 29). Therefore, although the rescue of AXIN2, PCNA and MMP13 
demonstrated that DKK1 successfully blocked the canonical pathway, its failure to rescue 
COL2A1, Aggrecan and SOX9 down-regulation suggested that these genes are regulated 
differently. 
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Figure 29: Stimulation of AHAC with DKK1 promotes their de-differentiation 
In the absence of exogenous WNT-3A, treatment with 100 ng/ml DKK1 resulted, as expected, in down-
regulation of the mRNA levels of AXIN2 and PCNA, but also in a paradoxical down-regulation of COL2A1 
and Aggrecan similar to that induced by WNT-3A. n=6 (3 donors; 2 samples/donor). Data were analysed 
with paired T-test. Gene expression values are expressed as percentage of the vehicle-treated cells. 
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The finding that DKK1 not only did not rescue WNT-3A-induced loss of phenotypic markers 
but, on its own promoted it, was indeed very puzzling. Scattered reports demonstrate that, in 
particular circumstances, WNT-3A can activate non-canonical Wnt pathways. For instance 
WNT-3A has been shown to promote intracellular calcium accumulation and CaMKII activation 
in HUVEC cells (Samarzija et al., 2009) and to induce bone formation through a G-protein and 
PKC-mediated mechanism (Tu et al., 2007). In addition, Dkk1 itself has been shown to promote 
CamKII phosphorylation in a different biological system (Mikheev et al., 2008). Therefore we 
argued that a plausible explanation for our paradoxical results would be that while 
proliferation (PCNA), MMP13 expression, and AXIN2 up-regulation are driven by 
activation of the canonical Wnt pathway, the loss of phenotypic markers (COL2A1, 
SOX9) and of extracellular matrix may be regulated through a different, Wnt/non-
canonical pathway which is antagonized by the canonical. This became the main 
hypothesis in the rest of this study.   
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WNT-3A SIMULTANEOUSLY ACTIVATES THE CANONICAL AND THE 
CA2+/CAMKII-DEPENDENT WNT PATHWAYS IN A DOSE-DEPENDENT 
MANNER 
To identify the signalling pathway through which WNT-3A induced chondrocyte de-
differentiation, we focused on the Wnt-Ca2+/CaMKII pathway because it has been shown to be 
active in chicken epiphyseal cartilage (Taschner et al., 2008) and to mediate Wnt signalling in 
Zebrafish and Xenopus embryos (Kuhl et al., 2000;Sheldahl et al., 1999;Slusarski et al., 
1997a;Slusarski et al., 1997b) antagonizing β-catenin. As a first approach, to test whether 
WNT-3A activates the non-canonical Ca2+/CaMKII-dependent pathway, I treated primary AHAC 
cultures with increasing doses of WNT-3A whilst monitoring calcium mobilization (as readout 
of the activation of the Ca2+-dependent pathway) and AXIN2 expression (as readout for the 
activation of the canonical pathway). In keeping with our hypothesis, WNT-3A elicited 
activation of both pathways; notably, Ca2+-mobilization occurred preferably at low doses and 
AXIN2 up-regulation at higher doses (Fig. 30A and B).  
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Figure 30: Dose-dependent intracellular Ca
2+
-accumulation and activation of the Wnt/β-catenin-
dependent pathway following treatment with WNT-3A 
(A) WNT-3A caused calcium mobilization in AHAC, particularly at low doses. Primary AHAC were treated 
with different doses of recombinant WNT-3A or vehicle control for 5 minutes and then subjected to 
fluorometric determination of calcium mobilization (n=9; 3 donors, 3 samples/donor). (B) Q-PCR for 
AXIN2 mRNA in primary chondrocytes exposed for 24 hours to different doses of recombinant WNT-3A. 
WNT-3A induced dose dependent up-regulation of AXIN2 in primary AHAC (n=3). Data were analysed by 
unpaired t-test in (A) and with Kruskal Wallis with Dunns post-test in (B). 
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WNT-3A PROMOTES INTRACELLULAR CALCIUM MOBILIZATION TROUGH A G-PROTEIN 
DEPENDENT MECHANISM 
In Zebrafish and Xenopus embryos, it was shown that the Ca2+/CaMKII pathway signals in a G-
protein dependent manner (Kuhl et al., 2000;Sheldahl et al., 1999;Slusarski et al., 1997a). 
Furthermore, WNT-3A has been recently proved to elicit G-protein-mediated properties of 
mammalians FZD receptors (Koval and Katanaev, 2011). To explore whether in articular 
chondrocytes, the calcium release demonstrated following WNT-3A treatment was G protein-
dependent, we used pertussis toxin (PTX), a Gαi, Gα0 and Gαt protein inhibitor (Sheldahl et al., 
1999;Slusarski et al., 1997a). In a collaborative effort with Joanna Sherwood, PhD student in 
our laboratory, we demonstrated that PTX treatment resulted in an efficient blockade of WNT-
3A-induced calcium mobilization (Fig. 31), thereby confirming a strong analogy between the 
Ca2+/CaMKII pathway activated by WNT-5A in Xenopus and what was being observed in 
articular chondrocytes in response to WNT-3A. 
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Figure 31: WNT-3A-mediated intracellular calcium accumulation is G-protein dependent 
AHAC were pre-incubated overnight at 37°C with 1μg/ml of the G-protein inhibitor PTX (pertussis toxin) 
and then treated for 5 minutes with 100ng/ml of WNT-3A or vehicle control. PTX treatment blocked 
calcium mobilization induced by WNT-3A (n=6; 3 donors, 2 samples/donor). Data were analysed by 
unpaired t-test. Experiment performed by Joanna Sherwood. 
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WNT-3A PROMOTES PHOSPHORYLATION AND NUCLEAR ACCUMULATION OF CAMKII 
IN HUMAN ARTICULAR CHONDROCYTES 
Encouraged by these results, we went on to evaluate the involvement of CaMKII. 
Phosphorylation in Thr286 (T286) is a key event in CaMKII activation (Griffith et al., 2003). As a 
first step we aimed at investigating whether WNT-3A treatment resulted in increased 
phosphorylation of T286. I treated AHAC with 100 ng/ml WNT-3A or vehicle control for 24 
hours and stained the monolayers with an antibody to detect the activated, phosphorylated 
form of CaMKII (Soderling, 1999). PhosphoCaMKII staining was increased in WNT-3A-treated 
samples, with increased nuclear localization, confirming the activation of this pathway (Fig. 
32A-F). Such phosphorylation was abrogated in presence of the selective CaMKII inhibitor 
KN93 (Fig. 32A). 
CaMKII phosphorylation was also detected by western blotting, after 15 minutes and 1 hour 
from the addition of WNT-3A to the cells (Fig. 33).  
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Figure 32: WNT-3A promotes CaMKII phosphorylation and nuclear translocation in AHAC 
(A) WNT-3A induced nuclear accumulation of the phosphorylated form of CaMKII. Immunofluorescence 
staining for pCaMKII in P0 AHAC stimulated for 24 hours with WNT-3A in combination with either the 
CaMKII inhibitor KN93 or its inactive analogue KN92 (both 10μM) (B-F). Quantification of the pCaMKII 
fluorescence intensity in the nuclear and in the cytoplasmic fractions of stimulated AHAC. The pixel 
intensity profile was plotted over a linear section of a whole cell (B-C). The nuclear and cytoplasmic 
fluorescence intensity was then calculated as the area under the curve (D-F). RFI=Relative Fluorescence 
Intensity. Scale bar in D =20µm. Statistical analysis was performed with unpaired t-test. 
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Figure 33: WNT-3A promotes CaMKII phosphorylation in AHAC 
100ng/ml of recombinant WNT-3A promoted phosphorylation of CaMKII in Thr286 after 15 minutes and 
1 hour from stimulation in AHAC. 
 
Taken together, my data indicate that exogenous application of WNT-3A, in addition to the 
activation of the Wnt-β-catenin pathway, also promotes intracellular calcium accumulation 
through a G-protein dependent mechanism. This phenomenon is also associated with 
phosphorylation and nuclear translocation of CaMKII. Activation of the Wnt/β-catenin or of the 
Ca2+/CaMKII pathways is dose-dependent, with low doses of WNT-3A activating the 
Ca2+/CaMKII and high doses the β-catenin pathways. 
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WNT-CANONICAL AND WNT-CAMKII NON CANONICAL PATHWAYS ARE 
RECIPROCALLY INHIBITORY IN AHAC 
In Xenopus, the Wnt/Ca2+/CaMKII pathway was shown to inhibit the Wnt-β-catenin dependent 
pathway (Kuhl et al., 2000;Sheldahl et al., 1999). This is interesting because reciprocal 
inhibition of the two pathways would explain why DKK1 alone cause de-differentiation in our 
model. To investigate the interaction between the CaMKII-pathway with the Wnt-canonical 
pathway following WNT-3A stimulation, I monitored the activation of the canonical pathway in 
WNT-3A-treated P0 AHAC (100ng/ml, a dose that activates both CaMKII and the β-catenin 
pathways) in the presence of the selective CaMKII inhibitor KN93, or its inactive analogue KN92 
(both 10µM) for 24 hours (Fig. 34). 
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Figure 34: Wnt-Ca
2+
/CaMKII pathway inhibits the activation of the Wnt-canonical pathway  
Q-PCR for AXIN2 of primary AHAC treated with 100ng/ml WNT-3A in the presence of the CaMKII 
inhibitor KN93 or its inactive analog KN92 (10μM). (n=8, 4 donors, 2 samples/donor). Statistical analysis 
was performed with ANOVA. 
 
CaMKII inhibition by KN93 significantly increased the WNT-3A-induced up-regulation of AXIN2 
mRNA (Fig. 34), thereby confirming that activation of CaMKII inhibits the Wnt/β-catenin 
pathway. In contrast KN92, which is structurally similar to KN93 but does not inhibit CaMKII 
(Marley and Thomson, 1996), did not alter the expression of AXIN2 (Fig. 34).  
To study if the Wnt-β catenin pathway modulates the Wnt-Ca2+/CaMKII pathway, I performed 
the reciprocal experiment in which Ca2+-mobilization was monitored in AHAC treated with 
WNT-3A in the presence or the absence of DKK1 (Fig. 35). 
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Figure 35: Wnt-canonical pathway inhibits the activation of the Ca
2+
/CaMKII pathway 
DKK1 promoted intracellular calcium accumulation in P0 AHAC. The inhibition of the canonical pathway 
with DKK1 enhanced intracellular calcium accumulation induced by WNT-3A. In all the experiments n=12 
(4 donors, 3 samples/donor). Data were analysed by unpaired T-test. 
 
Both WNT-3A and DKK1 stimulation resulted in statistically significant activation of Ca2+-
mobilization, which was further increased when DKK1 and WNT-3A were used together, 
thereby demonstrating that the selective inhibition of the canonical pathway enhances the 
activation of the Ca2+-mobilization (Fig. 35). The increased Ca2+ mobilization induced by DKK1 in 
the absence of exogenous WNT-3A might be due to the inhibition of the basal Wnt activation 
supported by endogenous Wnt ligands. 
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SFRP1 DOES NOT BLOCK WNT-3A MEDIATED INTRACELLULAR CALCIUM 
ACCUMULATION 
To gain a better insight into this mechanism and specifically if the selectivity of the blockade 
for the canonical pathway was essential for Ca2+-mobilization or whether general out-titration 
of Wnts also induced Ca2+ mobilization, we repeated the same experiment utilizing sFRP1 as a 
Wnt inhibitor instead of DKK1. We chose sFRP1 because it is known to bind and inhibit several 
Wnts including WNT-3A (Wawrzak et al., 2007;Galli et al., 2006) preventing their interaction 
with FZD receptors. This experiment was performed in collaboration with Dr Jessica Bertrand 
in our laboratory. 
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Figure 36: sFRP1 does not promote intracellular calcium accumulation 
P0 AHAC were incubated with 100ng/ml of sFRP1 alone or in combination with 100ng/ml of 
recombinant WNT-3A for 5 minutes and intracellular calcium accumulation was measured. sFRP1 alone 
did not promote intracellular calcium accumulation in P0 AHAC but partially inhibited WNT-3A mediated 
Ca
2+
 mobilization (n=12; 4 donors, 3 samples/donor). Statistical analysis performed by unpaired t-test. 
 
sFRP1 treatment prevented WNT-3A-induced intracellular calcium accumulation but, in 
contrast to DKK1, on its own, did not induce Ca2+-mobilization, thereby confirming that Ca2+-
mobilization induced by DKK1 is due to selective inhibition of the canonical pathway and 
consequent de-repression of the Ca2+/CaMKII pathway (Fig. 36). 
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Taken together, these data demonstrate reciprocal inhibition of the Wnt-β catenin and Wnt-
Ca2+/CaMKII pathways following WNT-3A stimulation in articular chondrocytes, and that the 
inhibition of one causes de-repression of the other.  
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WNT/-CATENIN PATHWAY AND WNT/CA2+/CAMKII PATHWAY 
REGULATES DISTINCT BIOLOGICAL PROCESSES IN AHAC 
Having demonstrated that WNT-3A can signal simultaneously through two intracellular 
pathways, we set out to discriminate CaMKII- from β-catenin-dependent transcriptional 
targets. To this end, I treated chondrocytes with WNT-3A in the presence of either the CaMKII 
inhibitor KN93, or the inactive compound KN92. 
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Figure 37: CaMKII inhibition does not alter chondrocyte phenotype 
Primary AHAC were treated for 24 hours with 10 μM KN93. Blockade of CaMKII with KN93 did not alter 
the basal levels of Aggrecan, COL2A1, and SOX9 n=6 (3 donors, 2 samples/donor). Statistical analysis 
was performed with paired t-test. 
 
Treatment of P0 AHAC with KN93 alone did not have any biological effect of the cells (Fig. 37). 
As expected, WNT-3A induced a significant down-regulation of COL2A1, Aggrecan and SOX9 
mRNA compared to control, but CaMKII blockade with KN93 resulted in a statistically 
significant rescue of COL2A1 and SOX9 expression (Fig. 38A and C), demonstrating that WNT-
3A-induced chondrocyte de-differentiation is, at least in part, CaMKII dependent. In contrast 
KN93 did not rescue the down-regulation of MMP13 mRNA (Fig. 38D). Therefore WNT-3A up-
regulates AXIN2 and PCNA through the canonical pathway and down-regulates SOX9 and 
COL2A1 in a CaMKII-dependent manner. 
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Figure 38: Inhibition of the Ca
2+/
CaMKII pathway rescued the loss of COL2A1 and SOX9 mRNA 
expression in AHAC. 
CaMKII blockade rescues WNT-3A- induced down-regulation of COL2A1 and SOX9 mRNA. Primary AHAC 
were cultured for 24 hours in the presence of 100ng/ml WNT-3A or vehicle control, and either the 
CaMKII inhibitor KN93 or the inactive control KN92 (both 10µM). Gene expression was evaluated by Q-
PCR. The values were normalized for β-actin and expressed as a percentage of the KN92-treated group 
(n=6; 3 donors, 2 samples/donor). Statistical analysis performed with paired T-test. 
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SPECIFICITY OF CA2+/CaMKII SIGNALLING: PMA-INDUCED CA2+-ACCUMULATION IS 
NOT SUFFICIENT TO DOWN-REGULATE COL2A1 AND SOX9 EXPRESSION 
Ca2+-mobilization is a priming event for the activation of several partially independent 
signalling pathways, including phospho-Inositol-3-kinase (PI3K), calcineurin, PKC and CaMKII 
pathways. To test the specificity of the Ca2+/CaMKII pathway activated by WNT-3A and 
resulting in COL2A1 and SOX9 down-regulation, we tested whether a non-specific Ca2+-
mobilization such as that induced by phorbol-12-myristate-13-acetate (PMA), could achieve 
the same result. 
PMA successfully promoted intracellular calcium mobilization in articular chondrocytes (Fig. 
39).  
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Figure 39: PMA induced Ca
2+
-mobilization in AHAC 
Treatment with 10ng/ml of PMA or 100ng/ml of WNT-3A for 5 minutes promoted intracellular calcium 
mobilization in AHAC (n=8, 4 donors, 2 samples/donor). Statistical analysis performed with unpaired t-
test. 
 
PMA-stimulation resulted in down-regulation of Aggrecan but not SOX9 or COL2A1 (Fig. 40). 
This, and the fact that instead CaMKII blockade rescued the expression of COL2A1 as well as 
SOX9, suggests that the WNT-3A-induced effects on these three genes rely specifically on 
CaMKII-dependent Ca2+-pathway. 
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Figure 40: PMA down-regulates Aggrecan in AHAC 
In contrast to WNT-3A PMA failed to down-regulate SOX9 and COL2A1. Aggrecan was instead 
statistically significantly down-regulated (n=6; 3 donors, 2 samples/donor). Statistical analysis 
performed by paired t-test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 132 
Blockade of the Ca2+/CaMKII pathway rescued the loss of the chondrocyte markers SOX9 and 
COL2A1 induced by WNT-3A (Fig.38). 
These results demonstrate that WNT-3A simultaneously activates the Wnt/β-catenin pathway 
and the Wnt/Ca2+/CaMKII pathways with different outcomes: WNT-3A in fact mediates 
proliferation through β-catenin activation and de-differentiation through CaMKII. 
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CAMKII IS ACTIVATED IN OSTEOARTHRITIC CARTILAGE 
Our data so far identify CaMKII as a key molecule mediating outcomes of Wnt signalling that 
can be postulated to be pathogenic in arthritis.  
It is therefore tempting to hypothesize that a switch of Wnt signalling from β-catenin to 
CaMKII may be a pathogenic event in OA development that transforms Wnt signalling from 
homeostatic to catabolic. If so, we would expect that CaMKII phosphorylation should be 
associated with OA lesions. Therefore, I compared the expression of pCaMKII on cartilage 
explants isolated from normal donors and from osteoarthritic patients (Mankin Score =6) (Fig. 
41). 
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Figure 41: CaMKII is phosphorylated only in the cartilage of OA patients 
Cartilage explants from OA patients (Mankin score ≥ 4) and from normal patients (n=3 for both 
conditions) were stained with anti pT286CaMKII. The phosphorylated and active form of the enzyme 
was expressed only in the cartilage from the OA patients. Images are representative of the cartilage of 
one OA (A-B) and one normal cartilage sample. 
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Indeed the phosphorylated form of CaMKII was expressed only in the cartilage of the OA 
patients and was completely absent in cartilage removed from normal donors.  
The expression of pCaMKII only in the cartilage from OA patients suggests that CaMKII might 
have an active role in the pathogenesis of OA.  
Previous data showed that overexpression of CaMKII in the epiphyseal cartilage in chicken can 
be associated with accelerated maturation and hypertrophy of the chondrocytes (Taschner et 
al., 2008). 
This is interesting because ectopic hypertrophic maturation has been described in articular 
chondrocytes in OA, and recently proven to drive cartilage breakdown (Saito et al., 2010;Yates 
et al., 2010). Therefore it would be very interesting to see whether Wnt-dependent CaMKII 
signalling controls such process, because pharmacological CaMKII blockers are commercially 
available. 
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CHAPTER 5: DISCUSSION 
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We have demonstrated that chondrocyte exposure to exogenous WNT-3A can simultaneously 
activate both the β-catenin-dependent and the G-protein-mediated Ca2+/CaMKII/pathways 
which are in equilibrium due to reciprocal inhibition (See Scheme in Fig. 42). These two 
pathways modulate the transcription of distinct target genes involved in different biological 
processes: WNT-3A promotes chondrocyte proliferation through β-catenin and differentiation 
through CaMKII. According to our model, blockade of the canonical/β-catenin pathway will 
also cause articular-chondrocyte de-differentiation, through de-repression of the CaMKII 
pathway (Fig. 42 and B).  
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Figure 42: Simultaneous activation and reciprocal inhibition of β-catenin and CaMKII dependent 
pathways in AHAC 
In AHAC, WNT-3A up-regulates AXIN2 expression and proliferation through the Wnt-canonical pathway 
(A), but induces loss of differentiation via a G-protein-mediated Ca
2+
/CaMKII dependent pathway (B). 
These two pathways are reciprocally inhibitory and in equilibrium (C). Therefore, either exogenous 
WNT-3A (C) or blockade of the canonical pathway with DKK1 (D-E) will both result in loss of chondrocyte 
phenotype. 
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This model may help explaining contradictions in the current literature. In particular, both 
activation or disruption of the canonical Wnt signalling results in chondrodysplasia with 
delayed maturation of chondrocytes (Akiyama et al., 2004;Enomoto-Iwamoto et al., 2002) and, 
in adulthood in cartilage breakdown (Chen et al., 2008;Koyama et al., 2008;Zhu et al., 
2008;Zhu et al., 2009). Similarly, in the mouse embryo (Yang et al., 2003;Yamaguchi et al., 
1999) both the overexpression and the knockout of WNT-5A, which in Zebrafish and Xenopus 
has been shown to activate the Ca2+/CaMKII pathway (Kuhl et al., 2000;Slusarski et al., 1997b) , 
result in a similar phenotype of chondrodysplasia, in both cases with reduced chondrocyte 
proliferation and hypertrophic maturation (Yang et al., 2003;Yamaguchi et al., 1999). Although 
this phenotype, in vivo, may be partially determined by compensatory mechanisms involving 
modulation of the Ihh-PTHrP pathway, COL2A1 expression was up-regulated in the growth 
plate of WNT-5A KO mice and down-regulated in mice overexpressing WNT-5A under the 
transcriptional control of the collagen type 2 promoter (Yang et al., 2003). In addition, in vitro, 
WNT-5A dose-dependently down-regulated the activity of a COL2A1 reporter in mouse 
chondrocytes. Importantly, this study showed that WNT-1, a well validated canonical Wnt, 
could also decrease COL2A1 reporter activity, but in a TCF-independent manner, since 
overexpression of TCF1 failed to achieve the same result (Yang et al., 2003). This may suggests 
that WNT-3A may not be the only canonical Wnt to signal through multiple pathways.  
At large in keeping with my data, Taschner et al. reported that forced activation of CaMKII in 
the chick epiphyseal cartilage, resulted in down-regulation of cell-cycle regulators and 
acceleration of hypertrophic differentiation (Taschner et al., 2008), which is notoriously 
associated with down-regulation of COL2A1 and SOX9 (Taschner et al., 2008;Lefebvre et al., 
1998). However, Taschner’s results cannot directly compared with ours, because of the 
intrinsically different biology of epiphyseal chondrocytes, which are destined to undergo 
hypertrophic differentiation and eventually replaced by bone, and the articular chondrocytes, 
which are resistant to hypertrophy and to endochondral bone formation. In addition, in 
Taschner's study, proliferation is driven by non-cell autonomous mechanisms including 
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secretion of Ihh and consequent PTHrP signalling. With all these limitations in comparing the 
experimental setups, our data, and a recent similar paper from Li et al. (Li et al., 2011) in which 
overexpression of constitutively active CaMKII was complemented by loss of function 
experiments, show the role of this kinase in the initiation of hypertrophy, a process that is 
associated with the loss of stable chondrocytes markers including SOX9 and COL2A1 (Lefebvre 
et al., 1998).  
Our findings have been recently published in the Journal of Cell Biology and have been 
commented by Kestler and Kuhl in an editorial in the same issue (Nalesso et al., 2011;Kestler 
and Kuhl, 2011). The two authors suggested that our model can help explaining other poorly 
understood phenomena happening in different biological systems. Wnt11 has been shown to 
drive dorso-ventral axis formation in Xenopus, but whereas it activates the Wnt/β-catenin 
pathway in the dorsal side of the embryo (Tao et al., 2005), it was shown to lead the ventral 
side formation through activation of the Ca2+/CaMKII pathway (Kuhl et al., 2000). These 
puzzling data can find explanation in our model, since Wnt11 is expressed at higher levels in 
the dorsal side and at lower concentrations in the ventral side (Schroeder et al., 1999), 
therefore supporting dorso/ventral axis polarization trough a gradient formation and the 
reciprocal inhibition of the Wnt/β-catenin and the Wnt/Ca2+/CaMKII pathways.  
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Figure 43: Different concentrations of Wnts can activate different signalling pathways 
The formation of a Wnt gradient in a tissue determines the activation of different signalling cascades (A- 
D). E) The inhibitory cross-regulation determines a Wnt-switch  
The reciprocal inhibition of the canonical and CaMKII dependent pathways activated by WNT-
3A may represent a hub through which different stimuli active in cartilage and known to 
influence CaMKII can dramatically influence the outcome of Wnt signalling by switching 
between β-catenin and CaMKII dependent target genes. Such stimuli include inflammatory 
molecules (Racioppi and Means, 2008;Pritchard and Guilak, 2006), biomechanics (Shimazaki et 
al., 2006;Valhmu and Raia, 2002), or PTHrP activity (Taschner et al., 2008). We are currently 
investigated these aspects in our group. 
Although we and others (Kuhl et al., 2000;Sheldahl et al., 1999;Slusarski et al., 1997a) have 
shown that Ca2+/CaMKII activation is GPCR dependent, it is still unclear how Wnts activate G 
proteins. In a recent paper, Koval and Katanev demonstrated the activation of G protein 
following WNT-3A stimulation in a different biological system (Koval and Katanev., 2011). In 
addition, based on the similarity between FZD receptors and other GPCR (Wang et al., 2006a) 
it is tempting to postulate that, in the absence of DKK-engaged LRP, FZD receptors may 
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function as GPCRs (Wang et al., 2006a). However, we cannot exclude that in our experimental 
system G-protein activation may be indirect, e.g. through the activation of a different GPCR. 
My data suggest that the CaMKII-dependent effects of WNT-3A are independent from LRP 
because they are not blocked, and rather enhanced, by DKK1. A separate issue is as to 
whether, in our system, individual FZD receptors can activate both pathways, or if the 
simultaneous activation of canonical and CaMKII pathway is due to the co-expression, on 
chondrocytes, of FZD receptors with different signalling specificity. Slusarski and colleagues 
demonstrated that in Zebrafish, expression of rat frizzled 2 receptor (Rfz-2), but not Rfz-1, 
increased intracellular calcium accumulation, which was further enhanced by the co-
expression of Xenopus Wnt-5a (Xwnt-5a)(Slusarski et al., 1997a). In addition, in a mammalian 
cell line Xwnt-5a, but not Xwnt-8, stimulated calcium accumulation via Rfz-2 in a PTX sensitive 
way (Liu et al., 1999). Subsequently, Kuhl at al. have demonstrated in Xenopus embryos that 
that Wnt-5a, but not canonical Wnts, induced Ca2+-mobilization, PKC and CaMKII activation, in 
a FZD specific manner. Only some FZD receptors were able to signal through CaMKII, and such 
signal was also strictly ligand-specific (Kuhl et al., 2000). 
We have demonstrated that AHAC express different FZD receptors (Fig. 17) known to mediate 
both the canonical (Kemp et al., 2007;Gazit et al., 1999;Terasaki et al., 2002;Karasawa et al., 
2002) and the Ca2+-dependent pathways (Kuhl et al., 2000;Nishita et al., 2010;Robitaille et al., 
2002). Therefore, it is possible that the receptor or of the co-receptor (Grumolato et al., 2010) 
repertoire of chondrocytes may determine the balance of the WNT-3A signalling.  
Alternatively, we cannot exclude that mechanisms downstream of FZD receptors may activate 
CaMKII: Ryu et al demonstrated that GSK3 inhibitor LiCl also down-regulated COL2A1 
expression (Ryu et al., 2002;Ryu and Chun, 2006) and Topol and colleagues (Topol et al., 2003) 
showed that WNT-5A can induce degradation of β-catenin even in the presence of LiCl, which 
is a canonical Wnt agonist and stabilizes β-catenin in a receptor-independent manner by 
inhibiting GSK3β (Topol et al., 2003).  
Discussion 
 143 
However, lithium is also an inhibitor of the inositol pathway (Berridge and Irvine, 1989), hence 
these data are of difficult to interpret.  
Whichever the mechanism, it is unlikely that in our system the activation of the Ca2+/CaMKII 
pathway is indirect, since Ca2+-mobilization occurred as early as 5 minutes following addition of 
WNT-3A. 
Equally, although it cannot be completely excluded, it is unlikely that exogenous WNT-3A may 
have caused promiscuous activation of receptors, first because Ca2+ release took place 
particularly at low doses of WNT-3A, whereas β-catenin activation was observed only at the 
higher doses, and, second, because DKK1 caused Ca2+ release and chondrocyte de-
differentiation also in the absence of exogenous WNT-3A (Figure 29, 35 and 42D-E), which 
cannot be explained by promiscuous receptor activation by supra-physiological levels of 
exogenous WNT-3A. In addition in our system, WNT-3A expression was indeed down-regulated 
in the most damaged areas of cartilage explants, this suggesting that alteration of the basal 
level of expression of Wnt ligands might bias the activation of different signalling pathways 
and disrupt the maintenance of chondrocyte homeostasis.  
In our system, activation of CaMKII was associated with its nuclear localization, which could be 
blocked with the CaMKII inhibitor KN93. A similar activation-dependent nuclear localization of 
phosphoCaMKII has been reported in smooth muscle cells (Cipolletta et al., 2010) and very 
recently in epiphyseal chondrocytes (Li et al., 2011) in vivo. WNT-3A itself has also been 
reported to promote nuclear localization of CaMKIV in hippocampal neurons (Arrazola et al., 
2009). Nuclear localization of CaMKII is regulated by several factors including splicing of a 
nuclear localization signal (NLS), phosphorylation of serines downstream of the NLS, and 
binding to anchoring and interacting molecules (Griffith et al., 2003). The specific function of 
the nuclear localization in this context is not known, however subcellular localization of CaMKII 
has been shown to restrict/regulate substrate specificity in different cell types or in response 
to other signals (Griffith et al., 2003;Tsui et al., 2005). Therefore it is tempting to speculate that 
CaMKII may have a nuclear function, either in mediating chondrocyte de-differentiation, or 
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suppression of the canonical pathway. In this regard it has been shown that CaMKII activation 
in colon cancer cells mediates nuclear export of TCF isoforms (Najdi et al., 2009). 
FUTURE PERSPECTIVES 
A novel and important aspect of this study is the discovery that Wnt/β-catenin and 
Wnt/Ca2+/CaMKII pathways have different transcriptional targets. 
Wnt signalling is an attractive therapeutic target for its demonstrated role on cartilage and 
joint homeostasis, but because of the multitude of processes regulated by these pathways, 
and the lack of information regarding their reciprocal interaction, it has not been possible until 
now to target it pharmacologically. The discovery that single Wnts can activate simultaneously 
different pathways, regulating distinct and possibly cell-specific transcriptional targets, 
represents an opportunity to achieve a higher degree of target specificity. Therefore, thanks to 
the availability of molecules and drugs that selectively can inhibit either GPCR-mediated 
signalling cascades (Lehmann et al., 2008;Sheldahl et al., 1999;Mukai et al., 1992;Freissmuth et 
al., 1996), CaMKII (Slater et al., 1999;Ishida et al., 1995;Sumi et al., 1991) or the canonical Wnt 
pathway (Huang et al., 2009;Trosset et al., 2006;Lu et al., 2009), we have planned to interfere 
at different levels with the WNT-3A activated pathways and to dissect their molecular targets, 
which potentially could be therapeutically relevant for the treatment of acute cartilage injuries 
and/or osteoarthritis.  
From a biochemical point of view, different aspects require a deeper analysis: at the moment 
we do not know whether the biochemical behaviour of WNT-3A is shared by other Wnts 
and/or if it is cell-context dependent. In addition, the expression of different FZD or other 
poorly characterized co-receptors -such as ROR1/2 or HSPGs- on the cell membrane might be 
different in pathologic conditions; this, in turn, could lead Wnt ligands to preferentially 
activate a pathway that physiologically they do not activate or they activate in a lesser extent. 
Of course, also the presence of cytokines or inflammatory molecules-such as IL-1 or TNFα- 
might influence Wnt signalling, as, for instance, they can activate Ca2+-mediated pathways 
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(Pritchard and Guilak, 2006). All these aspects are currently under investigation in our 
laboratory and will help understanding wnt biology in the adult cartilage tissue. 
Finally, we demonstrated that CaMKII is phosphorylated only in the articular cartilage of OA 
patients and not in normal cartilage: we currently do not know the biological meaning of this 
phenomenon, nor we know if the intracellular sub-localization of this kinase is relevant for its 
function and if it differs in physiologic vs pathologic conditions. Our data showed nuclear 
localization of CaMKII upon WNT-3A phosphorylation: it would be now interesting to evaluate 
whether this is necessary for the phosphorylation and consequent modulation of transcription 
factors -such as TCF/LEF and Sox9- and the relevance of this phenomenon for the maintenance 
of cartilage homeostasis. 
 
Too much Wnt signaling is detrimental but too little Wnt signalling has its own set of adverse 
sequelae. What happens if the Goldilocks principle is employed and Wnt signaling is 
modulated until it is “just right”?  
(Leucht et al., 2008) 
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The data included in the following chapters are of a methodological nature. Nevertheless this 
relatively large amount of work has been crucial for achieving the results reported in the 
previous chapters, and may be of interest to other investigators. Therefore, I felt that they 
could be presented as methodological Appendices. 
APPENDIX 1: TRANSFECTION OF HUMAN ARTICULAR CHONDROCYTES 
Transfection of exogenous DNA is a useful tool to evaluate the biological function of a gene or 
to assess if and how different types of stimuli might influence its transcription. 
Articular chondrocytes are notoriously very difficult to transfect and, to preserve their 
phenotype and behaviour, one should avoid too harsh treatments. Therefore a careful 
optimization was necessary. In order to maximise the transfection efficiency I have tried 
different transfection methods and compared their efficiency and cytotoxicity.  
LIPOSOMAL-BASED TRANSFECTION REAGENTS 
I first compared the efficiency of lipid-based transfection reagents such as Lipofectamine 2000 
(Invitrogen), Fugene 6 (Roche) and Fugene HD (Roche) by using a GFP-encoding expression 
vector on confluent P0 chondrocytes. The cells have been transfected with different ratios of 
transfection reagent/GFP-encoding vector (see Table 3 for summary) and transfection 
efficiency has been calculated as percentage of fluorescent cells/total number of cells.  
 
TABLE 3 
The plasmid/transfection reagent ratios have been expressed as volume of transfection reagent/µg 
plasmidic DNA  
 
 
 Trasfection reagent/GFP vector 
Lipofectamine 2000 1:2 1:1 2:1 
Fugene 6 3:1 3:2 6:1 
Fugene HD 3:2 5:2 8:2 
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Figure 44: Transfection of P0 AHAC with different ratios of Lipofectamine/GFP-encoding vector.  
A-B): Lipofectamine/GFP-vector ratio 1:2; C-D): ratio 1:1; E-F: ratio 2:1; G-H): lipofectamine only. The 
transfection efficiency has been assessed 24 hours post-transfection. 
 
 
 
 
 
A)                                                                                                                                                   B) 
    G)                                                                                                                                                      H) 
C)                                                                                                                                                     D) 
 E)                                                                                                                                                     F) 
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Figure 45: Transfection of P0 AHAC with different ratios of Fugene 6/GFP-encoding vector.  
A-B) Fugene 6/GFP-vector ratio 3:1; C-D) ratio 3:2; E-F) ratio 6:1; G-H): Fugene 6 only. 4X magnification. 
The transfection efficiency has been assessed 24 hours post-transfection. 
 
A)                                                                                                                                                       B) 
C)                                                                                                                                                        D) 
E)                                                                                                                                                        F) 
       G)                                                                                                                                                         H) 
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Figure 46:Transfection of P0 AHAC with different ratios of Fugene HD/GFP-encoding vector 
A-B) Fugene HD/GFP-vector ratio 3:2; C-D) ratio 5:2; D-F: ratio 8:2; F-G) Fugene HD only. 4X 
magnification. The transfection efficiency has been assessed 24 hours post-transfection. 
 
 
    A)                                                                                                                                                       B) 
   C)                                                                                                                                                       D) 
  E)                                                                                                                                                       F) 
 G)                                                                                                                                                      H) 
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Lipofectamine 2000 had an average transfection efficiency equal to 7% whereas the two other 
transfection reagents, Fugene 6 and Fugene HD did not reach the 5% (fig.44-46). No evident 
toxicity was recorded after 24 hours from transfection with all the reagents as evaluated with 
trypan Blue exclusion assay.  
TRANSFECTION OF NON-CONFLUENT AHAC WITH LIPOFECTAMINE 2000 
Lipofectamine 2000 had the highest transfection rate on confluent cells. In order to improve it, 
the transfection was attempted on non-confluent cells, with the most efficient ratio of 
lipofectamine 2000/GFP-vector (Fig. 47). 
 
 
 
 
 
 
 
 
 
 
Figure 47: Transfection of 50%-confluent P0 chondrocytes with Lipofectamine 2000 
A-B) Non-confluent primary P0 AHAH transfected with Lipofectamine 2000/GFP-vector, ratio 2:1, for 
24h C-D) Un-transfected cells. 4X magnification. Transfection efficiency has been evaluated 24h post-
transfection. 
 
The transfection of non-confluent cells improved the transfection efficiency of lipofectamine, 
which reached the 20%. Unfortunately, the cytotoxicity of the reagent increased along with 
the efficiency, as many of the transfection cells died 24 hours post-transfection. 
A)                                                                                                                                                                    B) 
C)                                                                                                                                                                    D) 
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LIPOFECTAMINE 2000 TIME COURSE 
To minimize the cytotoxic effect of Lipofectamine 2000, I incubated non-confluent 
chondrocytes with Lipofectamine/GFP-vector complexes for different periods of time. The 
transfection efficiency and cytotoxicity was then assessed by FACS analysis (Fig. 48 and 49) 
utilizing, as a measure of cell death, the size of the cell (See the Materials and Methods 
section). The FACS analysis was performed in collaboration with Dr. Fulvio d’Aquisto. 
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Figure 48: Time course of incubation with Lipofectamine 2000 
P0 articular chondrocytes were incubated with Lipofectamine/pGFP complexes for different time points. 
The cells were detached by trypsin digestion and subjected to FACS analysis. The gated events at each 
time point represent the number of alive and GFP-positive cells. Control cells=un-transfected 
chondrocytes. 
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Figure 49: Transfection efficiency and cytotoxicity of lipofectamine 2000 
a) Transfection efficiency of lipofectamine at different time points; b and c) chondrocyte survival rate. 
Data determined by FACS analysis. 
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The transfection efficiency of lipofectamine 2000 and its cytotoxic effect are time dependent 
and reached their maximum after 8 hours from transfection.  
NUCLEOFECTION 
In alternative to lipid-based transfection reagents an electroporation-based method was also 
evaluated. Electroporation consists in applying an electric field to the plasma membrane of a 
cell, increasing its permeability and allowing the introduction of polar molecules, such as DNA, 
in the cell. Nucleofection is a more efficient form of electroporation, which allows the direct 
introduction of the exogenous DNA, directly into the nucleus of the electroporated cells. 
Freshly isolated primary chondrocytes were nucleofected by using the appropriate kit for 
primary chondrocytes (Lonzabio). The cells have been electroporated by using both the pMAx-
eGFP encoding vector (eGFP), provided with the nucleofection kit, and with the GFP-encoding 
vector used in the experiment with the liposome-based transfection reagents (GFP). The 
transfection efficiency was measured by FACS analysis. The cytotoxicity was quantified by 
Trypan blue exclusion test. 
Nucleofection had ~40% transfection efficiency, with both eGFP and GFP encoding vectors (Fig. 
51E). The lethality rate recorded after 24 hours was around 30% for the eGFP- and 40% with 
the GFP-vector (Fig 51F). Unfortunately, at 48 hours post-electroporation, most of the 
remaining cells died (data not shown) making this transfection method unsuitable. 
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Figure 50: Nucleofection of primary chondrocytes 
A-B) Freshly isolated chondrocytes nucleofected with pMAX-eGFP-encoding vector C-D) Chondrocytes 
nucleofected with GFP encoding vector E-F) Chondrocytes nucleofected in absence of any plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
A)                                                                                                                                           B) 
C)                                                                                                                                            D) 
 
 
 
 
E)                                                                                                                                            F) 
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Figure 51: Quantification of the transfection efficiency of nucleofection on primary articular 
chondrocytes. 
Five hundred thousand human articular chondrocytes were isolated from two different donors and 
electroporated with two different vectors encoding for GFP by using the appropriate device for 
nucleofection (Lonzabio). The cells were then incubated overnight in standard growth conditions. The 
transfection efficiency was measured as percentage of fluorescent cells by FACS analysis. A and C) 
Circled in red, the percentage of cells transfected with pMAX-eGFP-encoding vector in donor 1 and 2. B 
and D) Circled in red, the percentage of cells transfected with a GFP-encoding vector in donor 1 and 2. e) 
Transfection efficiency of nucleofection with the two different GFP-encoding vectors. f) Trypan exclusion 
test n=3  
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TRANSFECTION WITH ATELOCOLLAGEN 
Atelocollagen (KOKEN) is highly purified calf dermis collagen type I enzimatically digested with 
pepsin. The digestion removes the C- and N-telopeptides from the molecule. The resulting 
cleaved protein has a highly conserved sequence across the species and consequently a very 
low immunogenicity (Honma et al., 2004).  
Atelocollagen has been proven to promote the introduction of functional siRNA in vivo (Diarra 
et al., 2007), and it has been shown to allow the transfection of siRNA and adenoviral vector in 
vitro, in different systems (Honma et al., 2004). 
Transfection with atelocollagen has been tried with two different approaches: in one 
experiment atelocollagen DNA was resuspended in atelocollagen 1% and the polymer was 
used to pre-coat the plate were the chondrocytes were seeded. In a second attempt, the cells 
were directly resuspended in different concentrations of atelocollagen diluted in complete 
medium. In both cases the concentration of DNA was maintained constant to 1µg/µl.  
Atelocollagen alone did not promote any transfection of primary chondrocytes in our system, 
(see Table 4 for summary). These results indicate that atelocollagen is unsuitable for the 
transfection of plasmid DNA in vitro in primary articular chondrocytes. Taken together, these 
results indicate lipofectamine 2000 as the transfection reagent with the higher transfection 
efficiency in articular chondrocytes. 
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Method 
Transfection 
efficiency 
Ratio transfection 
reagent/DNA (v/w) 
Survival rate 
Lipofectamine-confluent cells <5% 2:1 100% 
Lipofectamine-non confluent cells ~7% 2:1 50% 
Fugene 6 <5% 3:1 100% 
Fugene 6 <5% 3:2 100% 
Fugene 6 <5% 6:1 100% 
Fugene HD <5% 3:2 100% 
Fugene HD <5% 5:2 100% 
Fugene HD <5% 8:2 100% 
Cells seeded on atelocollagen 1% No transfection n/a n/a 
Cells resuspended in atelocollagen 
0.005-0.1% 
Progressive increase 
from no transfection 
with atelocollagen 
0.1%to <5% with 
atelocollagen 0.005% 
n/a n/a 
AMAXA-kit for primary human 
chondrocytes 
~40% n/a 50% 
 
TABLE 4 
The table summarizes the efficiency of all the transfection methods/conditions tested on primary 
articular chondrocytes 
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APPENDIX 2: FUNCTIONAL VALIDATION OF WNT-3A-CONTAINING 
SUPERNATANT FROM STABLY TRANSFECTED L CELLS AND TCF/LEF 
REPORTER ASSAY 
To evaluate if a 7% transfection efficiency was enough to promote a recordable biological 
response in primary chondrocytes, we performed a TOP-flash (TCF-optimal promoter) reporter 
assay (Molenaar et al., 1996) on WNT-3A stimulated cells. 
The TOPFlash reporter assay consists in transfecting the cell type of interest with a vector 
encoding for firefly luciferase under control the transcriptional control of a TCF-promoter. 
Specifically, I used an optimized vector, the SUPER8XTopFlash reporter vector (kind gift of Prof. 
R. Moon, University of Washington, USA), containing 7 TCF binding sites on the TCF promoter, 
in order to maximize the biological response of the cells. 
To validate the reporter assay I transfected HEK293 cells, which have a higher transfection rate 
that chondrocytes, with the Super8XTOPFlash reporter vector and I stimulated the cells for 24 
hours with three different concentrations of recombinant WNT-3A and with LiCl 10mM as 
positive control (Fig. 52A). 
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A)                                                                                 B) 
 
Figure 52: TCF/LEF reporter assay  
A) Seventy per cent confluent HEK293 cells were co-transfected with the Super8XTOP-Flash reporter 
vector and a vector encoding for Renilla firefly luciferase under control of CMV promoter. Twenty four 
hours after transfection the cells were stimulated with different doses of recombinant WNT-3A or 
10mM LiCl. 0.1%BSA in PBS was used as negative control for WNT-3A and 10mM NaCl. The cells were 
then lysed and luciferase activity recorded. B) Reporter assay performed on porcine articular 
chondrocytes. Data are expressed as firefly luciferase activity normalized for Renilla luciferase activity. 
n=3 
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Since WNT-3A stimulation promoted a dose-dependent increase in the luciferase activity in 
HEK293 cells (Fig. 52A), I then performed the reporter assay on porcine articular chondrocytes 
(Fig. 52B).  
WNT-3A successfully induced the activation of the reporter assay in porcine articular 
chondrocytes, this demonstrating that the transfection efficiency of lipofectamine is enough to 
perform gain of function experiments in primary chondrocytes.  
I also used this assay to titrate the content of secreted WNT-3A in a conditioned medium 
obtained by L-cells overexpressing WNT-3A. 
We compared different dilutions of the conditioned medium with different known 
concentrations of recombinant WNT-3A (Fig. 53). 
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Figure 53: Determination of the concentration of secreted WNT-3A in a conditioned medium 
HEK293 were transfected with the SUPER8XTOPFlash reporter vector and stimulated for 24 hours with 
dilutions 1/10 and 1/20 of the conditioned medium obtained by culture of L-cells stably transfected with 
a WNT-3A encoding vector (WNT-3A CM) or with medium removed from un-transfected cells (L-cells 
CM). The cells were also stimulated in parallel with different doses of recombinant WNT-3A. Data are 
expressed as firefly luciferase activity normalized for Renilla luciferase activity. n=3 B) The RLU of the 
different doses of recombinant WNT-3A were used to build-up a standard curve to determine the 
concentration of secreted WNT-3A in the conditioned medium. DRC= Dose Response Curve 
RLU=Relative Fluorescent Units 
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On the base of the standard curve obtained by plotting the values of Luminescence emitted by 
HEK293 cells stimulated with different known doses of recombinant WNT-3A, I determined the 
concentration of WNT-3A in the conditioned medium to be 200.70 ng/ml. I used this batch of 
medium diluted 1:2 for all the experiments performed with conditioned medium described in 
this thesis, in order to be able to compare these results with the ones obtained with the dose 
of recombinant protein used for all the other experiments (100ng/ml). 
SUMMARY OF RESULTS FROM APPENDIX 1 AND 2 
In vitro gain of function experiments are a useful tool to investigate the signalling pathways 
activated by the transcription of a specific gene in a particular biological context.  
Introduction of exogenous DNA in primary articular chondrocytes is made difficult by the 
presence of the thick extracellular matrix surrounding these cells. To overcome this problem, 
chondrocytes can be infected with viral vectors encoding for the gene of interest. Viral 
transduction has been proved to provide a high rate of transgene expression (Lu et al., 2005;Li 
et al., 2004) and might be transient or permanent depending on the viral vector used. 
Transient gene expression is less laborious, and can be also achieved with non-viral methods. 
Lipid-based transfection reagents such as Lipofectamine (Invitrogen), Fugene 6 and Fugene HD 
(Roche) exploit the ability of positively charged lipids to interact with DNA and to be up-taken 
by the cells through endocytosis. Atelocollagen, pepsin digested type I collagen defective of 
the two telopeptides, has been proved to successfully promote the introduction of exogenous 
nucleic acids both in vitro and in vivo (Honma et al., 2004). Finally electroporation, which 
transiently increases the permability of the cell membrane, has also been shown to promote 
chondrocyte transfection (Welter et al., 2004). 
I tried all these methods in order to find the one with the best transfection efficiency and the 
lowest cytotoxicity. Of all the non-viral transfection methods which have been tested, 
Lipofectamine 2000 had the best combination of these two parameters, reaching a 
transfection efficiency equal to 7% and a low toxicity after 4 hours from the transfection. In 
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addition, this method successfully allowed performing a reporter assay on primary cells, 
indicating its suitability for our in vitro experiments. 
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APPENDIX 3: STIMULATION OF ARTICULAR CHONDROCYTES IN VIVO IN THE 
ECTOPIC CARTILAGE FORMATION ASSAY 
To evaluate the biological effects of WNT-3A in an in vivo system, we exploited the unique 
ability of chondrocytes to form ectopic, stable, hyaline-like cartilage when implanted 
intramuscularly in nude mice (Dell'Accio et al., 2001).  
The ectopic cartilage formation assay has been shown to predict the successful outcome of ACI 
in human (Saris et al., 2009;Saris et al., 2008). ACI is a surgical procedure allowing the repair of 
articular cartilage injuries of limited size. It consists in the removal of the cartilage from a non-
bearing area of the joint, in the isolation and expansion in vitro of the articular chondrocytes 
and finally in their re-implantation in the zone of the area of the articular damage, where they 
contribute to the repair process. Only chondrocytes which maintain the expression of some 
specific biomarkers- such as COL2A1 and Aggrecan- during the expansion in culture can 
successfully contribute to the repair. The expression of these biomarkers correlates with the 
success of the cartilage formation assay in nude mice (Dell'Accio et al., 2001) as well as the 
clinical outcome of ACI in patients (Saris et al., 2009;Saris et al., 2008).  
One major problem in using this assay to evaluate the effects of WNT-3A on ectopic cartilage 
formation was the need to provide a constant supply of WNT-3A within the implant, with 
minimal manipulation of the chondrocytes, because such manipulations may per se influence 
the ectopic cartilage formation capacity.  
To achieve this goal we opted for a cell delivery system based on the co-injection of 
chondrocytes with a small aliquot of a cell line overexpressing WNT-3A.  
To test the validity of the system we first co-injected porcine articular chondrocytes with Cos7 
cells co-transfected with a GFP-encoding vector and with a MycHis-tagged GCP2 expressing 
plasmid (Fig. 54 and 55). GCP2 is a chemokine with very mild pro-inflammatory properties 
(Wuyts et al., 1997) and abundantly expressed and secreted by chondrocytes (Not shown). We 
decided to use this vector because we could test the ability of the cells to secrete the protein 
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in the implants by immunohistochemistry, and we could distinguish the protein from the 
endogenous form expressed by chondrocytes thanks to the presence of the tag. We have 
chosen to use porcine chondrocytes to perform the assay for the easier availability of the cells 
in comparison to human samples and for the higher number of cells obtainable from the same 
amount of cartilage. Porcine chondrocytes have been extensively tested in this model 
(Dell’Accio et al., unpublished results).  
In this pilot experiment we also growth-arrested the cells by treating them with mitomycin C 
5µg/ml for 2 hours at 37°C, in order to avoid the formation of the tumours in the legs of the 
injected mice.  
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Figure 54: Porcine chondrocytes do form cartilage implants when co-injected with GFP-transfected 
Cos7 cells 
A-B) Bright field and green fluorescence images of Cos7 cells transfected with pGFP. C-D) Toluidin blue-
haematoxylin/eosin staining of hyaline-like cartilage implant formed by freshly isolated porcine-
chondrocytes co-injected with transfected 10% Cos7 cells E-F) Haematoxylin/eosin staining of hyaline-
like cartilage implant formed by freshly isolated pig-chondrocytes co-injected with eGFP-transfected 
cells. All the pictures were taken with a 10X magnification and were modified by Photoshop 7.0 for best 
rendering the fluorescence/staining. 
 
Cos7 cells had a transfection efficiency of around 60% (Fig. 57A-B) and eGFP-fluorescence was 
detected in monolayer for two weeks after transfection (Data not shown). The treatment with 
Mitomycin C did not compromise their ability to express GFP (not shown).  
The co-injection did not impair the ability of the chondrocytes to form cartilage in vivo (Fig. 
57C-D). No infiltration of inflammatory cells was noticed after haematoxylin-eosin staining of 
the tissue (Fig. 57E-F). 
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Figure 55: Anti His immunostaining of cartilage implant formed by pig chondrocytes co-injected with 
Cos7 cell previously transfected with GCP2 Myc-His tagged.  
A) anti-His tag staining on frozen section of implant formed by co-injected cells B) DAPI staining on A, C) 
A and B merged D) Anti-His tag staining on frozen section of cartilage implant formed by pig 
chondrocytes injected alone E) DAPI staining of D, F) d and e merged. Images were modified by using 
Photoshop 7.0 for best rendering the staining 
 
Persistence of the cells in the implant was further confirmed by anti-His immunostaining which 
revealed tagged GCP2 in the tissue (Fig. 58A-C). The immunostaining was performed by Dr. El 
Tawil, in our laboratory.  
Having validated the method, we then tried to co-injected articular chondrocytes with WNT-3A 
overexpressing cells, to evaluate the biological effect of this ligand on chondrocyte phenotype 
in vivo.  
We co-injected growth-arrested L cells (L-WNT-3A) stably transfected to express WNT-3A 
(Willert et al., 2003) along with porcine articular chondrocytes. Wild type L cells were used for 
control injections. The use of L-cells was particularly advantageous since these are murine 
fibroblasts, and therefore I could still selectively monitor gene expression in co-injected human 
or porcine chondrocytes using species-specific PCR primers. I then optimized their growth 
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arrest testing three different doses of Mitomycin C in order not to compromise their viability 
and especially their capacity to secrete biologically active WNT-3A for at least 14 days (Fig. 56). 
Since 5 µg/ml of the compound weren’t enough to completely arrest the growth of the cells 
(Fig. 56F) and 15µg/ml compromised the viability of the cells (Fig. 56G) we opted for an 
intermediate dose (7.5ug/ml) to growth arrest the cells before the injection. Indeed this dose 
did not impair the viability of L-cells (Fig. 56L-M) but efficiently stopped their growth.  
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Figure 56: Mitomycin C treatment does not compromise the viability of L-cells 
A-K) L-cells were treated with different doses of mitomycin C and their viability was monitored for 14 
days L) 40000 L-cells were plated and treated with 7.5µg/ml of mitomycin C. After 2 days the cells were 
counted to evaluate the efficacy of the growth arresting treatment M) L-cells growth arrested with 
mitomycin C were maintained in culture for 14 days upon treatment. The treatment did not compromise 
their survival. Pictures were acquired at 10X magnification. Scale bars=20µm 
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Finally we tested if the mitomycin C could impair the ability of L-cells to secrete biologically 
active WNT-3A. In order to do so, we used conditioned medium from growth-arrested L-WNT-
3A cells to stimulate porcine articular chondrocytes transfected with the SUPER8XTOPFlash 
reporter vector (Fig. 57) 
 
Figure 57: Mitomycin C treatment does not impair the ability of L-WNT-3A cells to secrete WNT-3A 
To confirm that mitomycin C-growth-arrested  L-WNT-3A cells still produced biologically active WNT-3A, 
the conditioned medium (from the last change of medium) obtained 14 days following mitomycin C 
treatment was tested for the ability to activate the SUPER8XTOPFlash reporter assay in porcine articular 
chondrocytes. Indeed conditioned medium from L-WNT-3A cells, but not from control cells, activated 
the SUPER8XTOPFlash reporter. The mutagenized SUPER8XFOPFlash vector was used to control for 
specificity (n=4). Unpaired t-test was used for the statistical analysis. 
 
Mitomycin C treatment did not block the expression on secretion of biologically active WNT-
3A, since the conditioned medium from growth-arrested cells was still able to activate the 
TCF/LEF reporter assay in chondrocytes. 
Finally, we tested the ability of L-WNT-3A cells to promote chondrocyte de-differentiation in 
vivo when co-injected with porcine and human articular chondrocytes (See Fig. 24 and 26). As 
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discussed above, the experiment resulted indeed in de-differentiation of chondrocytes in the 
implants retrieved from mice co-injected with chondrocytes and L-WNT-3A.  
SUMMARY OF APPENDIX 3 
We validated a new, convenient and efficient method to test the biological effect of secreted 
stimuli on chondrocytes in an in vivo system. 
This assay is advantageous from different points of view: 
 This assay is a modified version of the validated “ectopic cartilage formation 
assay” which is a WELL ESTABLISHED, REPRODUCIBLE and CLINICALLY 
RELEVANT chondrogenesis assay 
 The easy access to different, commercially available cell lines, stably 
overexpressing and secreting biologically relevant molecules make this assay 
CONVENIENT and of QUICK and EASY EXECUTION 
 The co-injection of articular chondrocytes with the growth-arrested cell line 
AVOIDS THE MANIPULATION OF THE CHONDROCYTES -e.g. by viral infection-
which could affect per se  the outcome of the assay and delay the execution of 
the experiment, and that may require special facilities for their optimization-
eg. class II rooms for the manipulation of lentiviruses-. 
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